

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07D 413/12, A61K 31/47, C07D 215/46, 417/12, 401/12, A61P 43/00		A1	(11) International Publication Number: WO 00/47577 (43) International Publication Date: 17 August 2000 (17.08.00)
<p>(21) International Application Number: PCT/EP00/01150</p> <p>(22) International Filing Date: 10 February 2000 (10.02.00)</p> <p>(30) Priority Data: 9903266.6 12 February 1999 (12.02.99) GB 9926430.1 8 November 1999 (08.11.99) GB </p> <p>(71) Applicant (<i>for all designated States except US</i>): SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (<i>for US only</i>): COULTON, Steven [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). JOHNS, Amanda [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). PORTER, Roderick, Alan [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB).</p> <p>(74) Agent: BLAKEY, Alison, Jane; Corporate Intellectual Property, SmithKline Beecham, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> </p>	
<p>(54) Title: PHENYL UREA AND PHENYL THIOUREA DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS</p> <p>(57) Abstract</p> <p>The present invention provides phenyl urea and phenyl thiourea derivatives which are non-peptide antagonists of human orexin receptors, in particular orexin-1 receptors, of formula (I) in which: Z represents oxygen or sulfur; and R¹ to R⁷ represent various substituent groups; and pharmaceutically acceptable salts thereof. In particular, these compounds are of potential use in the treatment of obesity including obesity observed in Type 2 (non-insulin-dependent) diabetes patients and/or sleep disorders.</p>			
<p style="text-align: right;">(I)</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

PHENYL UREA AND PHENYL THIOUREA DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS

This invention relates to phenyl urea and phenyl thiourea derivatives and their use as pharmaceuticals.

Many medically significant biological processes are mediated by proteins 5 participating in signal transduction pathways that involve G-proteins and/or second messengers.

Polypeptides and polynucleotides encoding the human 7-transmembrane G-protein coupled neuropeptide receptor, orexin-1 (HFGAN72), have been identified and are disclosed in EP-A-875565, EP-A-875566 and WO 96/34877. Polypeptides and 10 polynucleotides encoding a second human orexin receptor, orexin-2 (HFGANP), have been identified and are disclosed in EP-A-893498.

Polypeptides and polynucleotides encoding polypeptides which are ligands for the orexin-1 receptor, e.g. orexin-A (Lig72A) are disclosed in EP-A-849361.

Orexin receptors are found in the mammalian host and may be responsible for many 15 biological functions, including pathologies including, but not limited to, depression; anxiety; addictions; obsessive compulsive disorder; affective neurosis/disorder; depressive neurosis/disorder; anxiety neurosis; dysthymic disorder; behaviour disorder; mood disorder; sexual dysfunction; psychosexual dysfunction; sex disorder; sexual disorder; schizophrenia; manic depression; delerium; dementia; severe mental retardation and dyskinesias such as 20 Huntington's disease and Gilles de la Tourett's syndrome; disturbed biological and circadian rhythms; feeding disorders, such as anorexia, bulimia, cachexia, and obesity; diabetes; appetite/taste disorders; vomiting/nausea; asthma; cancer; Parkinson's disease; Cushing's syndrome / disease; basophil adenoma; prolactinoma; hyperprolactinemia; hypopituitarism; hypophysis tumor / adenoma; hypothalamic diseases; Froehlich's syndrome; 25 adrenohypophysis disease; hypophysis disease; hypophysis tumor / adenoma; pituitary growth hormone; adrenohypophysis hypofunction; adrenohypophysis hyperfunction; hypothalamic hypogonadism; Kallman's syndrome (anosmia, hyposmia); functional or psychogenic amenorrhea; hypopituitarism; hypothalamic hypothyroidism; hypothalamic-adrenal dysfunction; idiopathic hyperprolactinemia; hypothalamic disorders of growth 30 hormone deficiency; idiopathic growth hormone deficiency; dwarfism; gigantism; acromegaly; disturbed biological and circadian rhythms; and sleep disturbances associated with such diseases as neurological disorders, neuropathic pain and restless leg syndrome, heart and lung diseases; acute and congestive heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ischaemic or 35 haemorrhagic stroke; subarachnoid haemorrhage; head injury such as sub-arachnoid haemorrhage associated with traumatic head injury; ulcers; allergies; benign prostatic hypertrophy; chronic renal failure; renal disease; impaired glucose tolerance; migraine; hyperalgesia; pain; enhanced or exaggerated sensitivity to pain, such as hyperalgesia, causalgia and allodynia; acute pain; burn pain; atypical facial pain; neuropathic pain; back 40 pain; complex regional pain syndromes I and II; arthritic pain; sports injury pain; pain related to infection, e.g. HIV, post-polio syndrome, and post-herpetic neuralgia; phantom limb pain; labour pain; cancer pain; post-chemotherapy pain; post-stroke pain; post-operative pain; neuralgia; conditions associated with visceral pain including irritable bowel

syndrome, migraine and angina; urinary bladder incontinence e.g. urge incontinence; tolerance to narcotics or withdrawal from narcotics; sleep disorders; sleep apnea; narcolepsy; insomnia; parasomnia; jet-lag syndrome; and neurodegenerative disorders, which includes nosological entities such as disinhibition-dementia-parkinsonism-amyotrophy complex; pallido-ponto-nigral degeneration, epilepsy, and seizure disorders.

5 Experiments have shown that central administration of the ligand orexin-A (described in more detail below) stimulated food intake in freely-feeding rats during a 4 hour time period. This increase was approximately four-fold over control rats receiving vehicle. These data suggest that orexin-A may be an endogenous regulator of appetite. Therefore, antagonists of its receptor may be useful in the treatment of obesity and diabetes, see *Cell*, 1998, **92**, 573-10 585.

There is a significant incidence of obesity in westernised societies. According to WHO definitions a mean of 35% of subjects in 39 studies were overweight and a further 22% clinically obese. It has been estimated that 5.7% of all healthcare costs in the USA are a consequence of obesity. About 85% of Type 2 diabetics are obese, and diet and exercise are of value in all diabetics. The incidence of diagnosed diabetes in westernised countries is typically 5% and there are estimated to be an equal number undiagnosed. The incidence of both diseases is rising, demonstrating the inadequacy of current treatments which may be either ineffective or have toxicity risks including cardiovascular effects. Treatment of diabetes with sulphonylureas or insulin can cause hypoglycaemia, whilst metformin causes GI side-effects. No drug treatment for Type 2 diabetes has been shown to reduce the long-term complications of the disease. Insulin sensitizers will be useful for many diabetics, however they do not have an anti-obesity effect.

20 Rat sleep/EEG studies have also shown that central administration of orexin-A, an agonist of the orexin receptors, causes a dose-related increase in arousal, largely at the expense of a reduction in paradoxical sleep and slow wave sleep 2, when administered at the onset of the normal sleep period. Therefore antagonists of its receptor may be useful in the treatment of sleep disorders including insomnia.

The present invention provides phenyl urea and phenyl thiourea derivatives which are 30 non-peptide antagonists of human orexin receptors, in particular orexin-1 receptors. In particular, these compounds are of potential use in the treatment of obesity including obesity observed in Type 2 (non-insulin-dependent) diabetes patients and/or sleep disorders.

Several phenyl urea derivatives are known in the literature, viz:
WO 93/18028, WO 94/14801 and WO 94/18170 disclose indolylurea,
35 benzo[b]thienylurea and N-phenyl-N'-heteroarylurea derivatives respectively [compounds a)-i] below] as 5HT_{2C} receptor antagonists;

JP 04178362 discloses the compound N-(2-methyl-4-quinolinyl)-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)urea [compound j] below] as an agrochemical pesticide;
EP 123146 discloses the compound N-(2-methyl-4-quinolinyl)-N'-(3,4,5-trimethoxyphenyl)urea [compound k] below] as an anti-inflammatory agent;
40 GB 2009155 and *J. Am. Chem. Soc.*, 1956, **78**, 3703, disclose various N-phenyl-N'-(2-methyl-4-quinolinyl)urea derivatives [compounds m)-r] and compounds s)-w] below respectively];


J. Serb. Chem. Soc., 1993, 58(10), 737-43, discloses the synthesis of the compound N-(1,2-dihydro-6-methyl-2-oxo-4-quinolinyl)-N'-phenylthiourea [compound x] below;

none of these documents suggest the use of phenyl urea derivatives as orexin receptor antagonists.

5 International Patent Applications PCT/GB98/02437 and PCT/EP99/03100 (published after the priority date of the present application) disclose various phenyl urea derivatives as orexin receptor antagonists.

10 The present invention relates to N-phenyl-N'-(2-substituted-quinolinyl)urea derivatives which are non-peptide antagonists of human orexin receptors, in particular orexin-1 receptors. In particular, these compounds are of potential use in the treatment of obesity including obesity observed in Type 2 (non-insulin-dependent) diabetes patients and/or sleep disorders.

15 Thus according to the invention there is provided a compound of formula (I):



in which:

Z represents oxygen or sulfur;

20 R¹ represents (C₁₋₆)alkyl, (C₂₋₆)alkenyl or (C₁₋₆)alkoxy, any of which may be optionally substituted; halogen, R⁸CO- or NR⁹R¹⁰CO-;

R², R³, R⁴, R⁵ and R⁶ independently represent (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkoxy or (C₁₋₆)alkylthio, any of which may be optionally substituted; hydrogen, halogen, nitro, cyano, aryloxy, aryl(C₁₋₆)alkyloxy, aryl(C₁₋₆)alkyl, R⁸CO-, R⁸SO₂NH-, R⁸SO₂O-, R⁸CON(R¹¹)-, NR⁹R¹⁰-, NR⁹R¹⁰CO-, -COOR⁹, R¹¹C(=NOR⁸), heterocyclyl or heterocyclyl(C₁₋₆)alkyl;

25 or an adjacent pair of R², R³, R⁴, R⁵ and R⁶ together with the carbon atoms to which they are attached form an optionally substituted carbocyclic or heterocyclic ring;

R⁷ is (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkoxy or (C₁₋₆)alkylthio, any of which may be optionally substituted; halogen, hydroxy, nitro, cyano, NR⁹R¹⁰-, NR⁹R¹⁰CO-, N₃, -OCOR⁹ or R⁸CON(R¹¹)-;

30 R⁸ is (C₁₋₆)alkyl, (C₂₋₆)alkenyl, heterocyclyl, heterocyclyl(C₁₋₆)alkyl, heterocyclyl(C₂₋₆)alkenyl, aryl, aryl(C₁₋₆)alkyl or aryl(C₂₋₆)alkenyl, any of which may be optionally substituted;

R⁹ and R¹⁰ independently represent hydrogen, (C₁₋₆)alkyl, (C₂₋₆)alkenyl, heterocyclyl, heterocyclyl(C₁₋₆)alkyl, aryl or aryl(C₁₋₆)alkyl, any of which may be optionally substituted;

R¹¹ is hydrogen or (C₁₋₆)alkyl; and

n is 0, 1, 2, 3 or 4;

or a pharmaceutically acceptable salt thereof;

provided that the compound is not:

- a) N-(2-methyl-4-quinolinyl)-N'[3-(trifluoromethyl)phenyl]urea;
- 5 b) N-(4-methoxyphenyl)-N'-(2-methyl-4-quinolinyl)urea;
- c) N-[3-(dimethylamino)phenyl]-N'-(2-methyl-4-quinolinyl)urea;
- d) N-(3-methoxyphenyl)-N'-(2-methyl-4-quinolinyl)urea;
- e) ethyl 3-[[[(2-methyl-4-quinolinyl)amino]carbonyl]amino]benzoate;
- f) N-[3-hydroxyphenyl]-N'-(2-methyl-4-quinolinyl)urea;
- 10 g) N-[2,3-dichlorophenyl]-N'-(2-methyl-4-quinolinyl)urea;
- h) N-benzo[b]thien-5-yl-N'-(2-methyl-4-quinolinyl)urea;
- i) N-(1-methyl-1H-indol-5-yl)-N'-(2-methyl-4-quinolinyl)urea;
- j) N-(2-methyl-4-quinolinyl)-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)urea;
- k) N-(2-methyl-4-quinolinyl)-N'-(3,4,5-trimethoxyphenyl)urea;
- 15 l) N-(2-methylphenyl)-N'-(2-methyl-4-quinolinyl)urea;
- m) N-(4-methylphenyl)-N'-(2-methyl-4-quinolinyl)urea;
- n) N-(3,5-dimethylphenyl)-N'-(2-methyl-4-quinolinyl)urea;
- o) N-(4-chlorophenyl)-N'-(2-methyl-4-quinolinyl)urea;
- p) N-(2-methyl-4-quinolinyl)-N'[3-(trifluoromethyl)phenyl]urea;
- 20 q) N-(2-methoxyphenyl)-N'-(2-methyl-4-quinolinyl)urea;
- r) N-(2-methyl-4-quinolinyl)-N'-phenylurea;
- s) N-(3,4-dimethylphenyl)-N'-(2-methyl-4-quinolinyl)urea;
- t) N-(4-methyl-2-nitrophenyl)-N'-(2-methyl-4-quinolinyl)urea;
- 25 u) N-(3-chloro-4-methylphenyl)-N'-(2-methyl-4-quinolinyl)urea;
- v) N-(5-chloro-2-methoxyphenyl)-N'-(2-methyl-4-quinolinyl)urea;
- w) 1-(6-amino-2-methyl-4-quinolinyl)-3-(o-nitrophenyl)urea; or
- x) N-(1,2-dihydro-6-methyl-2-oxo-4-quinolinyl)-N'-phenylthiourea.

In formula (I) Z is preferably oxygen.

When a halogen atom is present in the compound of formula (I) this may be fluorine, chlorine, bromine or iodine.

n is preferably 1 or 2, more preferably 2.

When n is 1, the group R¹ is preferably in the 6- or 8-position, particularly the 8-position.

When n is 2, the groups R¹ are preferably in the 5,8- or 6,8-positions, particularly the 5,8-positions.

R¹ is preferably halogen e.g. fluoro, or (C₁₋₆)alkoxy e.g. methoxy. R¹ is most preferably fluoro.

When any one of R¹ to R¹¹ comprise a (C₁₋₆)alkyl group, whether alone or forming part of a larger group, e.g. alkoxy or alkylthio, the alkyl group may be straight chain, branched or cyclic, or combinations thereof, it preferably contains 1 to 4 carbon atoms, and is most preferably methyl or ethyl.

When any one of R¹ to R¹⁰ comprise a (C₂₋₆)alkenyl group, whether alone or forming part of a larger group, the alkenyl group may be straight chain, branched or cyclic, or combinations thereof, it preferably contains 2 to 4 carbon atoms and is most preferably allyl.

Suitable optional substituents for (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkoxy and (C₁₋₆)alkylthio groups include one or more substituents selected from halogen e.g. fluoro, (C₁₋₄)alkoxy e.g. methoxy, hydroxy, carboxy and (C₁₋₆)alkyl esters and (C₁₋₆)alkylamides thereof, amino, mono- or di-(C₁₋₆)alkylamino, N(R¹¹)COR⁸, N(R¹¹)SO₂R⁸, CONR⁹R¹⁰ and cyano. For example one or more substituents selected from halogen e.g. fluoro, (C₁₋₄)alkoxy e.g. methoxy, hydroxy, carboxy and (C₁₋₆)alkyl esters thereof, amino, mono- or di-(C₁₋₆)alkylamino and cyano.

When used herein the term "aryl", whether alone or forming part of a larger group, includes optionally substituted aryl groups such as phenyl and naphthyl, preferably phenyl. The aryl group may contain up to 5, more preferably 1, 2 or 3 optional substituents. Suitable substituents for aryl groups include halogen, (C₁₋₆)alkyl e.g. methyl, (C₁₋₆)haloalkyl e.g. trifluoromethyl, (C₁₋₆)alkoxy e.g. methoxy, (C₁₋₆)alkoxy(C₁₋₆)alkyl e.g. methoxymethyl, hydroxy, =O, carboxy and (C₁₋₆)alkyl esters and (C₁₋₆)mono and dialkylamides thereof, nitro, arylsulfonyl e.g. p-toluenesulfonyl, (C₁₋₆)alkylsulfonyl e.g. methanesulfonyl, aryl(C₁₋₆)alkyl e.g. benzyl or 3-phenylpropyl, aryl e.g. phenyl, hydroxy(C₁₋₆)alkyl e.g. hydroxyethyl, R^aCO₂⁻, R^aCO₂(C₁₋₆)alkyl e.g. carboethoxypropyl, cyano, cyano(C₁₋₆)alkyl e.g. 3-cyanopropyl, R^aR^bN, R^aR^bN(C₁₋₆)alkyl, R^aR^bNCO(C₁₋₆)alkyl in which R^a and R^b are independently selected from hydrogen and (C₁₋₆)alkyl.

When any one of R² to R⁶, R⁸, R⁹ or R¹⁰ represent heterocyclyl or heterocyclyl(C₁₋₆)alkyl the heterocyclyl group is preferably a 5- to 10-membered monocyclic or bicyclic ring, which may be saturated or unsaturated, for example containing 1, 2 or 3 heteroatoms selected from oxygen, nitrogen and sulfur; for example pyrrolidine, oxazole, morpholine, pyrimidine or phthalimide. A ring containing one or two nitrogen atoms is especially preferred. The heterocyclyl group may contain up to 5, more preferably 1, 2 or 3 optional substituents. Suitable substituents for heterocyclyl groups include those mentioned above for aryl groups.

When an adjacent pair of R² to R⁶ together with the carbon atoms to which they are attached form a carbocyclic or heterocyclic ring this is preferably a 5- to 7-membered ring, which may be aromatic or non-aromatic. Heterocyclic rings preferably contain 1, 2 or 3 heteroatoms selected from oxygen, nitrogen and sulfur; for example oxazole, imidazole, thiophene, pyran, dioxan, pyrrole or pyrrolidine. A ring containing one nitrogen atom and one oxygen atom is preferred. It is particularly preferred for the nitrogen to be attached directly to the R⁴ position. A carbocyclic or heterocyclic ring formed by an adjacent pair of R² to R⁶ together with the carbon atoms to which they are attached may be optionally substituted on carbon or nitrogen by one or more substituents, e.g. up to 3 substituents. Suitable substituents for the carbocyclic or heterocyclic ring include those mentioned above for aryl groups.

A preferred group of compounds are those in which R² to R⁶ independently represent hydrogen, R⁸CO-, NR⁹R¹⁰CO- wherein R⁹ is preferably represents hydrogen and R¹⁰ preferably represents (C₁₋₆)alkyl, halogen, (C₁₋₆)alkoxy e.g. methoxy, (C₁₋₆)alkylthio e.g. methylthio, or NR⁹R¹⁰ wherein R⁹ and R¹⁰ preferably represent (C₁₋₆)alkyl e.g. dimethylamino, and at least one of R² to R⁶ is other than hydrogen; or an adjacent pair of R² to R⁶ together


with the carbon atoms to which they are attached form an optionally substituted 5- to 7-membered carbocyclic or heterocyclic ring, e.g. a 6- or 7-membered non-aromatic heterocyclic ring, a 5- or 6-membered non-aromatic carbocyclic ring or a 5- or 6-membered aromatic heterocyclic ring.

5 A further preferred group of compounds are those in which R², R⁵ and R⁶ represent hydrogen.

A further preferred group of compounds are those in which R², R⁴ and R⁶ represent hydrogen.

10 A preferred group of compounds are those in which either R³ and R⁴, or R³ and R⁵ are other than hydrogen.

A group of compounds which may be mentioned are the compounds of formula (Ia):



(Ia)

15 in which:

Z represents oxygen or sulfur;

R¹ represents (C₁₋₆)alkyl, (C₂₋₆)alkenyl or (C₁₋₆)alkoxy, any of which may be optionally substituted; halogen, R⁸CO- or NR⁹R¹⁰CO-;

20 R², R³, R⁴, R⁵ and R⁶ independently represent (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkoxy or (C₁₋₆)alkylthio, any of which may be optionally substituted; hydrogen, halogen, nitro, cyano, aryloxy, aryl(C₁₋₆)alkyloxy, aryl(C₁₋₆)alkyl, R⁸CO-, R⁸SO₂NH-, R⁸CON(R¹¹)-, NR⁹R¹⁰-, NR⁹R¹⁰CO-, -COOR⁹, heterocyclyl or heterocyclyl(C₁₋₆)alkyl;

or an adjacent pair of R², R³, R⁴, R⁵ and R⁶ together with the carbon atoms to which they are attached form an optionally substituted carbocyclic or heterocyclic ring;

25 R⁷ is (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkoxy or (C₁₋₆)alkylthio, any of which may be optionally substituted; halogen, hydroxy, nitro, cyano, NR⁹R¹⁰-, NR⁹R¹⁰CO-, N₃, -OCOR⁹ or R⁸CON(R¹¹)-;

R⁸ is (C₁₋₆)alkyl or aryl;

30 R⁹ and R¹⁰ independently represent hydrogen, (C₁₋₆)alkyl, aryl or aryl(C₁₋₆)alkyl;

R¹¹ is hydrogen or (C₁₋₆)alkyl; and

n is 0, 1, 2 or 3;

or a pharmaceutically acceptable salt thereof;

provided that the compound is not:

a) N-(2-methyl-4-quinolinyl)-N'-[3-(trifluoromethyl)phenyl]urea;

- b) N-(4-methoxy)-N'-(2-methyl-4-quinolinyl)urea;
- c) N-[3-(dimethylamino)phenyl]-N'-(2-methyl-4-quinolinyl)urea;
- d) N-(3-methoxyphenyl)-N'-(2-methyl-4-quinolinyl)urea;
- e) Ethyl 3-[[[(2-methyl-4-quinolinyl)amino]carbonyl]amino]benzoate;
- 5 f) N-[3-hydroxyphenyl]-N'-(2-methyl-4-quinolinyl)urea;
- g) N-[2,3-dichlorophenyl]-N'-(2-methyl-4-quinolinyl)urea;
- h) N-benzo[b]thien-5-yl-N'-(2-methyl-4-quinolinyl)urea;
- i) N-(1-methyl-1H-indol-5-yl)-N'-(2-methyl-4-quinolinyl)urea;
- j) N-(2-methyl-4-quinolinyl)-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)urea;
- 10 k) N-(2-methyl-4-quinolinyl)-N'-(3,4,5-trimethoxyphenyl)urea;
- l) N-(2-methylphenyl)-N'-(2-methyl-4-quinolinyl)urea;
- m) N-(4-methylphenyl)-N'-(2-methyl-4-quinolinyl)urea;
- n) N-(3,5-dimethylphenyl)-N'-(2-methyl-4-quinolinyl)urea;
- o) N-(4-chlorophenyl)-N'-(2-methyl-4-quinolinyl)urea;
- 15 p) N-(2-methyl-4-quinolinyl)-N'-[3-(trifluoromethyl)phenyl]urea;
- q) N-(2-methoxyphenyl)-N'-(2-methyl-4-quinolinyl)urea;
- r) N-(2-methyl-4-quinolinyl)-N'-phenylurea;
- s) N-(3,4-dimethylphenyl)-N'-(2-methyl-4-quinolinyl)urea;
- t) N-(4-methyl-2-nitrophenyl)-N'-(2-methyl-4-quinolinyl)urea;
- 20 u) N-(3-chloro-4-methylphenyl)-N'-(2-methyl-4-quinolinyl)urea;
- v) N-(5-chloro-2-methoxyphenyl)-N'-(2-methyl-4-quinolinyl)urea;
- w) 1-(6-amino-2-methyl-4-quinolinyl)-3-(o-nitrophenyl)urea; or
- x) N-(1,2-dihydro-6-methyl-2-oxo-4-quinolinyl)-N'-phenylthiourea.

In the compounds of formula (Ia) suitable substituents for aryl groups and for heterocyclyl groups when any one of R² to R⁶ represent heterocyclyl or heterocyclyl(C₁₋₆)alkyl include halogen, (C₁₋₄)alkyl e.g. methyl, (C₁₋₄)haloalkyl e.g. trifluoromethyl, (C₁₋₄)alkoxy e.g. methoxy, (C₁₋₄)alkoxy(C₁₋₄)alkyl e.g. methoxymethyl, hydroxy, carboxy and (C₁₋₆)alkyl esters, amino, nitro, arylsulfonyl e.g. p-toluenesulfonyl, and (C₁₋₄)alkylsulfonyl e.g. methanesulfonyl. Suitable substituents for carbocyclic or heterocyclic rings when an adjacent pair of R² to R⁶ together with the carbon atoms to which they are attached form carbocyclic or heterocyclic ring include (C₁₋₄)alkyl e.g. methyl, (C₁₋₄)alkoxy, (C₁₋₄)alkoxy(C₁₋₄)alkyl e.g. methoxymethyl, hydroxy, =O, aryl(C₁₋₄)alkyl e.g. benzyl or 3-phenylpropyl, aryl e.g. phenyl, hydroxy(C₁₋₄)alkyl e.g. hydroxyethyl; R^aCO₂, R^aCO₂(C₁₋₄)alkyl e.g. carboethoxypropyl, cyano, cyano(C₁₋₄)alkyl e.g. 3-cyanopropyl, R^aR^bN and R^aR^bN(C₁₋₄)alkyl in which R^a and R^b are independently selected from hydrogen and (C₁₋₄)alkyl.

A further group of compounds of formula (Ia) are those in which R² to R⁶ independently represent hydrogen, halogen, (C₁₋₆)alkoxy e.g. methoxy, (C₁₋₆)alkylthio e.g. methylthio, or NR⁹R¹⁰ wherein R⁹ and R¹⁰ preferably represent (C₁₋₆)alkyl e.g. dimethylamino, and at least one of R² to R⁶ is other than hydrogen; or an adjacent pair of R² to R⁶ together with the carbon atoms to which they are attached form an optionally substituted 5- to 7-membered heterocyclic ring, e.g. a 6- or 7-membered non-aromatic heterocyclic ring or a 5- or 6-membered aromatic heterocyclic ring.


Particular compounds according to the invention include those mentioned in the examples and their pharmaceutically acceptable salts.

It will be appreciated that for use in medicine the salts of the compounds of formula (I) should be pharmaceutically acceptable. Suitable pharmaceutically acceptable salts will be apparent to those skilled in the art and include for example acid addition salts formed with inorganic acids e.g. hydrochloric, hydrobromic, sulfuric, nitric or phosphoric acid; and organic acids e.g. succinic, maleic, acetic, fumaric, citric, tartaric, benzoic, p-toluenesulfonic, methanesulfonic or naphthalenesulfonic acid. Other salts e.g. oxalates, may be used, for example in the isolation of compounds of formula (I) and are included within the scope of this invention. Also included within the scope of the invention are solvates and hydrates of compounds of formula (I).


The invention extends to all isomeric forms including stereoisomers and geometric isomers of the compounds of formula (I) including enantiomers and mixtures thereof e.g. racemates. The different isomeric forms may be separated or resolved one from the other by conventional methods, or any given isomer may be obtained by conventional synthetic methods or by stereospecific or asymmetric syntheses.

Since the compounds of formula (I) are intended for use in pharmaceutical compositions it will readily be understood that they are each preferably provided in substantially pure form, for example at least 60% pure, more suitably at least 75% pure and preferably at least 85%, especially at least 98% pure (% are on a weight for weight basis). Impure preparations of the compounds may be used for preparing the more pure forms used in the pharmaceutical compositions.

According to a further feature the invention provides a process for the preparation of the compounds of formula (I) and salts thereof which comprises coupling a compound of formula (II):



with a compound of formula (III):



wherein A and B are appropriate functional groups to form the -NHCONH- or -NHCSNH- moiety when coupled; n is as defined in formula (I); and R¹ to R⁷ are R¹ to R⁷ as defined in formula (I) or groups convertible thereto; and thereafter optionally and as

necessary and in any appropriate order, converting any R¹ to R⁷ when other than R¹ to R⁷ respectively to R¹ to R⁷, and/or forming a pharmaceutically acceptable salt thereof.

Suitable examples of groups A and B are:

(i) A and B are -NH₂

5 (ii) one of A and B is -CON₃ and the other is -NH₂

(iii) one of A and B is -CO₂H and the other is -NH₂

(iv) one of A and B is -N=C=O and the other is -NH₂

(v) one of A and B is -N=C=S and the other is -NH₂

(vi) one of A and B is -NHCOL and the other is -NH₂

10 (vii) one of A and B is halogen and the other is -NHCONH₂

(viii) one of A and B is NHCOCBr₃ and the other is NH₂

Wherein L is a leaving group such as chloro or bromo, imidazole or phenoxy or phenylthio optionally substituted for example with halogen, for example chlorine.

When A and B are both -NH₂, the reaction is generally effected in the presence of a 15 urea coupling agent such as 1,1'-carbonyldiimidazole or triphosgene.

When one of A and B is -CO₂H and the other is -NH₂ the reaction is generally effected in the presence of an agent such as diphenylphosphoryl azide and in the presence of a base such as triethylamine.

When one of A and B is -N=C=O or -N=C=S and the other is -NH₂ the reaction is 20 suitably carried out in an inert solvent for example dimethylformamide or dichloromethane and/or toluene at ambient or elevated temperature, preferably ambient.

When one of A and B is -CON₃ or -CO₂H and the other is -NH₂ the reaction is suitably carried out in an inert solvent for example toluene or dimethylformamide at elevated temperature.

25 Where one of A and B is -NHCOL and the other is -NH₂, the reaction is suitably carried out in an inert solvent such as dichloromethane at ambient temperature optionally in the presence of a base, such as triethylamine or in dimethylformamide at ambient or elevated temperature.

When one of A and B is halogen and the other is -NHCONH₂ the reaction is 30 suitably carried out in an inert solvent such as toluene at elevated temperature, optionally in the presence of base.

When one of A and B is -NHCOCBr₃ and the other is NH₂ the reaction is suitably carried out in an inert solvent such as dimethylsulfoxide or pyridine at elevated temperatures in the presence of a base such as DBU.

35 Suitable examples of compounds having groups R¹ to R⁷ which are convertible to R¹ to R⁷ respectively include compounds where one or more of R² to R⁷ are OH or NH₂; and compounds where an adjacent pair of R² to R⁶ together with the carbon atoms to which they are attached represent a fused pyrrole ring which is unsubstituted on nitrogen, where treatment with a base, e.g. sodium hydride, and reaction with an electrophile, e.g. methyl iodide, benzyl chloride or benzenesulfonyl chloride, affords the corresponding substituent on the pyrrole nitrogen.

40 Compounds of formula (II) and (III) where A or B is -NH₂, -N=C=S or halogen are known compounds or can be prepared analogously to known compounds.

Compounds of formula (II) and (III) where A or B is -N=C=O may be prepared by treating a compound of formula (II) or (III) in which:

(i) A or B is -NH₂, with phosgene or a phosgene equivalent, in the presence of excess base or an inert solvent.

5 (ii) A or B is -CON₃, via the nitrene, by thermal rearrangement using conventional conditions (L.S. Trifonov *et al*, *Helv. Chim. Acta*, 1987, **70**, 262).

(iii) A or B is -CONH₂, via the nitrene intermediate using conventional conditions.

Compounds of formula (II) and (III) where A or B is -NHCOL may be prepared by reacting a compound of formula (II) or (III) in which A or B is -NH₂ with phosgene or a phosgene equivalent, in an inert solvent, at low temperature, if necessary in the presence of a base such as triethylamine. Examples of phosgene equivalents include triphosgene, 1,1'-carbonyldiimidazole, phenyl chloroformate and phenyl chlorothioformate.

10 Compounds of formula (II) and (III) where A or B is -NHCONH₂ can be prepared from compounds of formula (II) or (III) where A or B is -NH₂ by reaction with an inorganic isocyanate under conventional conditions.


15 Compounds of formula (II) and (III) where A or B is -NHCOCBr₃ can be prepared from compounds of formula (II) or (III) where A or B is -NH₂ by reaction with tribromoacetyl chloride in an inert solvent such as dichloromethane in the presence of a base such as triethylamine.

20 The compounds of formula (I) may be prepared singly or as compound libraries comprising at least 2, for example 5 to 1,000 compounds, and more preferably 10 to 100 compounds of formula (I). Libraries of compounds of formula (I) may be prepared by a combinatorial 'split and mix' approach or by multiple parallel synthesis using either solution phase or solid phase chemistry, by procedures known to those skilled in the art.

25 Thus according to a further aspect of the invention there is provided a compound library comprising at least 2 compounds of formula (I), or pharmaceutically acceptable salts thereof.

Novel intermediates of formulae (II) and (III) are also part of this invention.

According to a further feature the invention provides a compound of formula (II):



(II)

wherein A is -NH₂, -CON₃, -NH₂, -CO₂H, -N=C=O, -N=C=S, -NHCOL, halogen or -NHCOCBr₃, L is a leaving group, n is as defined in formula (I) and R^{1'} and R⁷ are R¹ and R⁷ as defined in formula (I) or groups convertible thereto.

35 Pharmaceutically acceptable salts may be prepared conventionally by reaction with the appropriate acid or acid derivative.

As indicated above the compounds of formula (I) and their pharmaceutically acceptable salts, without provisos a)-x), are useful for the treatment of diseases or disorders

where an antagonist of a human orexin receptor is required especially feeding disorders, such as obesity and diabetes; prolactinoma; hypoprolactinemia, hypothalamic disorders of growth hormone deficiency; idiopathic growth hormone deficiency; Cushing's syndrome/disease; hypothalamic-adrenal dysfunction; dwarfism; sleep disorders; sleep

5 apnea; narcolepsy; insomnia; parasomnia; jet-lag syndrome; and sleep disturbances associated with such diseases as neurological disorders, neuropathic pain, restless leg syndrome, heart and lung diseases, mental illness such as depression or schizophrenia, and addictions; sexual dysfunction; psychosexual dysfunction; sex disorder; sexual disorder; bulimia; and hypopituitarism.

10 The compounds of formula (I) and their pharmaceutically acceptable salts, without provisos a)-x), are particularly useful for the treatment of obesity, including obesity associated with Type 2 diabetes, and sleep disorders.

Other diseases or disorders which may be treated in accordance with the invention include disturbed biological and circadian rhythms; adrenohypophysis disease; hypophysis disease; hypophysis tumor / adenoma; adrenohypophysis hypofunction; functional or psychogenic amenorrhea; adrenohypophysis hyperfunction; migraine; hyperalgesia; pain; enhanced or exaggerated sensitivity to pain such as hyperalgesia, causalgia and allodynia; acute pain; burn pain; atypical facial pain; neuropathic pain; back pain; complex regional pain syndromes I and II; arthritic pain; sports injury pain; pain related to infection, e.g. 15 HIV, post-polio syndrome and post-herpetic neuralgia; phantom limb pain; labour pain; cancer pain; post-chemotherapy pain; post-stroke pain; post-operative pain; neuralgia; and tolerance to narcotics or withdrawal from narcotics.

20 The present invention also provides a method of treating or preventing diseases or disorders where an antagonist of a human orexin receptor is required, which comprises administering to a subject in need thereof an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, without provisos a)-x).

25 The present invention also provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, without provisos a)-x), for use in the treatment or prophylaxis of diseases or disorders where an antagonist of a human orexin receptor is required.

30 The present invention also provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, without provisos a)-x), in the manufacture of a medicament for the treatment or prophylaxis of diseases or disorders where an antagonist of a human orexin receptor is required.

35 For use in medicine, the compounds of the present invention are usually administered as a pharmaceutical composition. The present invention also provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

40 The compounds of formula (I) and their pharmaceutically acceptable salts, without provisos a)-x), may be administered by any convenient method, for example by oral, parenteral, buccal, sublingual, nasal, rectal or transdermal administration and the pharmaceutical compositions adapted accordingly.

The compounds of formula (I) and their pharmaceutically acceptable salts, without provisos a)-x), which are active when given orally can be formulated as liquids or solids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges.

5 A liquid formulation will generally consist of a suspension or solution of the compound or physiologically acceptable salt in a suitable liquid carrier(s) for example an aqueous solvent such as water, ethanol or glycerine, or a non-aqueous solvent, such as polyethylene glycol or an oil. The formulation may also contain a suspending agent, preservative, flavouring and/or colouring agent.

10 A composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations. Examples of such carriers include magnesium stearate, starch, lactose, sucrose and cellulose.

15 A composition in the form of a capsule can be prepared using routine encapsulation procedures. For example, pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.

20 Typical parenteral compositions consist of a solution or suspension of the compound or physiologically acceptable salt in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil. Alternatively, the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration.

25 Compositions for nasal administration may conveniently be formulated as aerosols, drops, gels and powders. Aerosol formulations typically comprise a solution or fine suspension of the active substance in a physiologically acceptable aqueous or non-aqueous solvent and are usually presented in single or multidose quantities in sterile form in a sealed container, which can take the form of a cartridge or refill for use with an atomising device. Alternatively the sealed container may be a unitary dispensing device such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve which is intended for 30 disposal once the contents of the container have been exhausted. Where the dosage form comprises an aerosol dispenser, it will contain a propellant which can be a compressed gas such as compressed air or an organic propellant such as a fluorochlorohydrocarbon or hydrofluorocarbon. The aerosol dosage forms can also take the form of a pump-atomiser.

35 Compositions suitable for buccal or sublingual administration include tablets, lozenges and pastilles, wherein the active ingredient is formulated with a carrier such as sugar and acacia, tragacanth, or gelatin and glycerin.

Compositions for rectal administration are conveniently in the form of suppositories containing a conventional suppository base such as cocoa butter.

40 Compositions suitable for transdermal administration include ointments, gels and patches.

Preferably the composition is in unit dose form such as a tablet, capsule or ampoule.

The dose of the compound of formula (I), or a pharmaceutically acceptable salt thereof, without provisos a)-x), used in the treatment or prophylaxis of the abovementioned disorders or diseases will vary in the usual way with the particular disorder or disease being treated, the weight of the subject and other similar factors. However as a general rule
5 suitable unit doses may be 0.05 to 1000 mg, more suitably 0.05 to 500 mg; such unit doses may be administered more than once a day for example two or three times a day, so that the total daily dosage is in the range of about 0.01 to 100 mg/kg; and such therapy may extend for a number of weeks or months. In the case of physiologically acceptable salts the above figures are calculated as the parent compound of formula (I), without provisos a)-x).

10 No toxicological effects are indicated/expected when a compound of formula (I), without provisos a)-x), is administered in the above mentioned dosage range.

Human orexin-A referred to above has the amino acid sequence:

pyroGlu Pro Leu Pro Asp Cys Cys Arg Gln Lys Thr Cys Ser Cys Arg Leu

1 5 10 15

15 Tyr Glu Leu Leu His Gly Ala Gly Asn His Ala Ala Gly Ile Leu Thr

20 25 30

Leu-NH₂

Orexin-A can be employed in a process for screening for compounds (antagonists) which inhibit the ligand's activation of the orexin-1 receptor.

20 In general, such screening procedures involve providing appropriate cells which express the orexin-1 receptor on the surface thereof. Such cells include cells from mammals, yeast, *Drosophila* or *E. coli*. In particular, a polynucleotide encoding the orexin-1 receptor is employed to transfect cells to thereby express the receptor. The expressed receptor is then contacted with a test compound and an orexin-1 receptor ligand to observe inhibition of a functional response.

One such screening procedure involves the use of melanophores which are transfected to express the orexin-1 receptor. Such a screening technique is described in WO 92/01810.

Another such screening technique involves introducing RNA encoding the orexin-1 receptor into *Xenopus* oocytes to transiently express the receptor. The receptor oocytes may 30 then be contacted with a receptor ligand and a compound to be screened, followed by detection of inhibition of a signal in the case of screening for compounds which are thought to inhibit activation of the receptor by the ligand.

Another method involves screening for compounds which inhibit activation of the receptor by determining inhibition of binding of a labelled orexin-1 receptor ligand to cells 35 which have the receptor on the surface thereof. Such a method involves transfecting a eukaryotic cell with DNA encoding the orexin-1 receptor such that the cell expresses the receptor on its surface and contacting the cell or cell membrane preparation with a compound in the presence of a labelled form of an orexin-1 receptor ligand. The ligand can be labelled, e.g. by radioactivity. The amount of labelled ligand bound to the receptors is measured, e.g. 40 by measuring radioactivity of the receptors. If the compound binds to the receptor as determined by a reduction of labelled ligand which binds to the receptors, the binding of labelled ligand to the receptor is inhibited.

Yet another screening technique involves the use of FLIPR equipment for high throughput screening of test compounds that inhibit mobilisation of intracellular calcium ions, or other ions, by affecting the interaction of an orexin-1 receptor ligand with the orexin-1 receptor. The ligand used in the screening method described below to determine the 5 antagonist activity of compounds according to the invention is orexin-A which has the amino acid sequence shown above.

All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully 10 set forth.

The following Examples illustrate the preparation of pharmacologically active compounds of the invention. In the Examples ^1H NMR's were measured at 250MHz in d_6 -DMSO unless otherwise stated. All hydrochloride salts unless otherwise stated were prepared by dissolving/suspending the free-base in methanol and treating with an excess of 15 ethereal HCl (1M).

Description 1: 4-Amino-5,8-difluoro-2-methylquinoline (D1)

Step 1: 4-Hydroxy-5,8-difluoro-2-methylquinoline - A mixture of 2,5-difluoroaniline (7.5ml) and ethyl acetoacetate (9.6ml) were combined in toluene (15ml) containing acetic acid (1.5ml). The mixture was boiled under Dean-Stark azeotrope conditions, cooled and 20 solvent removed at reduced pressure to give crude (E)-3-(2,5-difluoro-phenylamino)-but-2-enoic acid ethyl ester (16.17g). (E)-3-(2,5-Difluoro-phenylamino)-but-2-enoic acid ethyl ester (2g) was refluxed in Dowtherm-A (40ml) for 3h. After cooling the Dowtherm was diluted with pentane (40ml) and the precipitated title compound isolated by filtration. (Method A). ^1H NMR δ : 2.34 (3H, s), 5.91 (1H, s), 6.96 (1H, m), 7.53 (1H, m), 11.48 (1H, 25 brs).

OR:

A mixture of 2,5-difluoroaniline (10.0g), ethyl acetoacetate (9.85ml) and polyphosphoric acid (62ml) were heated with stirring at 180°C for 5h. The mixture was cooled to room temperature and neutralised with dilute NH₄OH/ice. The title compound precipitated and 30 was separated by filtration to give compound identical spectroscopically with a sample prepared by the two stage process described above.

Step 2: 4-Chloro-5,8-difluoro-2-methylquinoline - 4-Hydroxy-5,8-difluoro-2-methylquinoline (5.4g) in phosphoryl chloride (60ml) was boiled for 4h. The mixture was cooled to room temperature, excess phosphoryl chloride removed at reduced pressure, the 35 residue dissolved in ethyl acetate, washed with sodium hydrogen carbonate, dried (Na₂SO₄) and solvent removed at reduced pressure. The title compound (5.35g) was isolated as a brown powder. (Method B). ^1H NMR δ : 2.61 (3H, s), 7.46 (1H, m), 7.66 (1H, m), 7.81 (1H, s).


Step 3: 4-Azido-5,8-difluoro-2-methylquinoline - 4-Chloro-5,8-difluoro-2-methylquinoline (8.18g) in dimethylformamide (80ml) was treated with sodium azide (3.7g) and the mixture heated for 20h. The mixture was cooled, poured into ice/water and extracted with dichloromethane (2 x 200ml). The organic phase was washed with water, dried (Na₂SO₄) and solvent removed at reduced pressure. The residue was column

chromatographed (silica gel (5 - 20% diethyl ether in pentane) to give the title compound (5.45g) as a colourless solid. (Method C). ^1H NMR δ : 2.67 (3H, s), 7.29 (1H, m), 7.54 (1H, s), 7.58 (1H, m).

Step 4: 4-Amino-5,8-difluoro-2-methylquinoline - 4-Azido-5,8-difluoro-2-methylquinoline (0.55g) was suspended in methanol (20ml) and sodium borohydride (200mg) added. After 1h additional sodium borohydride (0.4g) was added and stirring continued for a further 3h. Solvent was removed at reduced pressure and the residue dissolved in 2N HCl (10ml). Excess sodium hydroxide was added and the title compound (0.44g) collected by filtration as a yellow solid. (Method D). ^1H NMR (CDCl_3) δ : 2.60 (3H, s), 5.28 (2H, brs), 6.47 (1H, s), 6.90 (1H, m), 7.19 (1H, m), 7.26 (1H, s).

Descriptions 2 - 10 were prepared by standard methods illustrated by Description 1 using an appropriately substituted aniline (using steps 1-4 of D1) or where commercially available a 4-hydroxy- (using steps 2 - 4 of D1) or 4-chloroquinoline (using steps 3 - 4 of D1).

15



Compound	R ¹	X	method	yield	NMR/MS (API ⁺)
Description 2: 4-Amino-6,8-difluoro-2-methylquinoline (D2)					
4-Hydroxy-6,8-difluoro-2-methylquinoline is commercially available from Maybridge					
D2 (step 2)	6,8-diF	Cl	B	81%	^1H NMR (CDCl_3) δ : 2.59 (3H, s), 7.70 (1H, m), 7.85 (2H, m)
D2 (step 3)	6,8-diF	N ₃	C	74%	^1H NMR (CDCl_3) δ : 2.67 (3H, s), 7.46 (1H, m), 7.54 (1H, s), 7.75 (1H, m)
D2 (step 4)	6,8-diF	NH ₂	D	76%	^1H NMR (CDCl_3) δ : 2.42 (3H, s), 6.51 (1H, s), 6.79 (2H, brs), 7.48 (1H, m), 7.76 (1H, m)
Description 3: 4-Amino- 8-fluoro-2-methylquinoline (D3)					
4-Chloro-8-fluoro-2-methylquinoline is commercially available from Ubichem					
D3 (step 3)	8-F	N ₃	C	89%	^1H NMR δ : 2.68 (3H, s), 7.49 (1H, s), 7.47 - 7.70 (m, 2H), 7.76 (1H, d, J = 7.0Hz)
D3 (step 4)	8-F	NH ₂	D	80%	^1H NMR δ : 2.43 (3H, s), 6.49 (1H, s), 6.79 (2H, brs), 7.22 - 7.40 (2H, m), 7.89 (1H, d, J = 8.2Hz)
Description 4: 4-Amino- 5,6-difluoro-2-methylquinoline (D4)					
D4 (step 1)	5,6-diF	OH	A	76*	contains 80% of 6,7-difluororegioisomer
D4 (step 2)	5,6-diF	Cl	B	7.4%	214, 216
D4 (step 3)	5,6-diF	N ₃	C	96%	^1H NMR (CDCl_3) δ : 2.72 (3H, s), 7.07 (1H, s), 7.48 - 7.59 (1H, m), 7.73 - 7.79 (1H, m)
D4 (step 4)	5,6-diF	NH ₂	D	86%	195 MH ⁺
Description 5: 4-Amino- 5,7-difluoro-2-methylquinoline (D5)					

D5 (step 1)	5,7-diF	OH	A	47%	196 MH ⁺
D5 (step 2)	5,7-diF	Cl	B	92%	214, 216 MH ⁺
D5 (step 3)	5,7-diF	N ₃	C	55%	193 (M+H - 28)
D5 (step 4)	5,7-diF	NH ₂	D	85%	195 MH ⁺

Description 6: - 4-Amino- 6-chloro-2-methylquinoline (D6)

D4, 6-dichloro-2-methylquinoline is commercially available from Ubichem

D6 (step 3)	6-Cl	N ₃	C	95%	191, 193 (M+H - 28)
D6 (step 4)	6-Cl	NH ₂	D	92%	193, 195 MH ⁺

Description 7: 4-Amino- 7,8-difluoro-2-methylquinoline (D7)

D7 (step 1)	7,8-diF	OH	A	35%	¹ H NMR δ: 2.37 (3H, s), 5.97 (1H, s), 7.28 - 7.38 (1H, m), 7.84 - 7.90 (1H, m), 11.70 (1H, brs)
D7 (step 2)	7,8-diF	Cl	B	83%	214, 216 MH ⁺
D7 (step 3)	7,8-diF	N ₃	C	87%	193 (M+H - 28)
D7 (step 4)	7,8-diF	NH ₂	D	77%	195 MH ⁺

Description 8: 4-Amino-6-fluoro-2-methylquinoline (D8)

D4-Chloro-6-fluoro-2-methylquinoline is commercially available from Ubichem

D8 (step 3)	6-F	N ₃		87%	175 (M+H - 28)
D8 (step 4)	6-F	NH ₂		98%	177 MH ⁺

Description 9: 4-Amino-8-bromo-2methylquinoline (D9)

D8-Bromo-4-chloro-2-methylquinoline is commercially available from Ubichem

D9 (step 3)	8-Br	N ₃	C	74%	234, 236 (M+H - 28)
D9 (step 4)	8-Br	NH ₂	D	97%	238 MH ⁺

Description 10: 4-Amino-8-chloro-2,7-dimethylquinoline (D10)

D10 (step 1)	8-Cl, 7-Me	OH	A	38%	¹ H NMR (CDCl ₃) δ: 2.46 (3H, s), 2.52 (3H, s), 7.15 (1H, s), 7.20 (1H, d, J = 8.5Hz), 8.14 (1H, d, J = 8.5Hz), 8.36 (1H, brs)
D10 (step 2)	8-Cl, 7-Me	Cl	B	95%	¹ H NMR (CDCl ₃) δ: 2.64 (3H, s), 2.73 (3H, s), 7.41 (1H, s), 7.45 (1H, d, J = 8.5Hz), 8.01 (1H, d, J = 8.5Hz)
D10 (step 3)	8-Cl, 7-Me	N ₃	C	63%	¹ H NMR (CDCl ₃) δ: 2.62 (3H, s), 2.80 (3H, s), 7.03 (1H, s), 7.33 (1H, d, J = 8.5Hz), 7.82 (1H, d, J = 8.5Hz)
D10 (step 4)	8-Cl, 7-Me	NH ₂		94%	¹ H NMR δ: 2.43 (3H, s), 2.51 (3H, s), 6.45 (1H, s), 6.75 (2H, brs), 7.27 (1H, d, J = 8.5Hz), 7.96 (1H, d, J = 8.5Hz)

¹H NMR and/or mass spectra were consistent with the structures in the table.**Description 11: 4-Amino-2-methyl-8-vinylquinoline (D11)**

A mixture of D9 (0.50g), lithium chloride (0.265g), tributylvinyl tin (0.73g) and

5 bis(triphenylphosphine)palladium(II)chloride (0.05g) in dimethylformamide (20ml) was heated at 100°C for 20h. Solvent was removed at reduced pressure, the residue dissolved in

dichloromethane, filtered and solvent removed at reduced pressure. The residue was extracted with diethyl ether, the extracts evaporated to dryness and the residue column chromatographed (silica gel, 0 - 10% methanol [containing 1% ammonia] in dichloromethane eluant) to give the title compound (0.13g). ¹H NMR δ: 2.51 (3H, s), 5.39 (1H, d), 5.93 (1H, d), 6.51 (1H, s), 7.14 (2H, brs), 7.40 (1H, m), 7.76 - 7.91 (2H, m), 8.10 (1H, d).

5 **Description 12: 2-Methylthioquinoline-4-carboxylic acid (D12)**
Step 1: 2-Methylthioquinoline-4-carboxylic acid methyl ester - 2-Chloroquinoline-4-carboxylic acid methyl ester (0.5g) (DE 3721222) in dimethylformamide (10ml) was treated
10 with sodium thiomethoxide (0.16g) and heated at 80°C for 2h. Solvent was removed at reduced pressure triturated with dichloromethane and filtered through celite. Solvent was reduced to 2ml and petroleum ether (40 - 60) added. The precipitated product (0.40g) was separated by filtration to give 2-methylthioquinoline-4-carboxylic acid methyl ester. m/z (API⁺): 234 (MH⁺).

15 **Step 2: 2-Methylthioquinoline-4-carboxylic acid** - 2-Methylthioquinoline-4-carboxylic acid methyl ester (0.40g) in methanol:2N sodium hydroxide (2:1, 45ml) was heated at 60°C until all solid had dissolved. Volume of solvent was reduced to (15ml) at reduced pressure and acidified with 2N HCl (16ml). The precipitated solid was separated by filtration and dried to give the title compound (0.39g). ¹H NMR δ: 2.68 (3H, s), 7.56 (1H, m), 7.75 - 7.80 (2H, m), 7.96 (1H, d, J = 8.2Hz), 8.55 (1H, d), 13.91 (1H, brs).

20 **Description 13: 2-Fluoroquinoline-4-carboxylic acid (D13)**
Step 1: 2-Fluoroquinoline-4-carboxylic acid methyl ester - 2-Chloroquinoline-4-carboxylic acid methyl ester (1.14g) in dimethylsulfone (4.0g) was treated with potassium fluoride (2.5g) and heated at 180°C for 1h. The reaction mixture was cooled to room
25 temperature, diluted with dichloromethane:water (1:1, 200ml), the organic phase separated, solvent removed at reduced pressure and the residue column chromatographed (silica gel, dichloromethane eluant) to give 2-fluoroquinoline-4-carboxylic acid methyl ester (0.7g). ¹H NMR (CDCl₃) δ: 3.99 (3H, s); 7.57 (2H, m); 7.72 (1H, m), 7.95 (1H, d, J = 8.5Hz), 8.67 (1H, d, J = 8.4Hz). m/z (API⁺): 205 (MH⁺).

30 **Step 2: 2-Fluoroquinoline-4-carboxylic acid** - A solution of 2-fluoroquinoline-4-carboxylic acid methyl ester (0.08g) in dichloromethane (4ml) was cooled to -50°C and boron tribromide (0.08ml) was added. After the addition of boron tribromide the reaction was warmed to room temperature and stirred for 1.5h. The mixture was re-cooled to -50°C, quenched with water (10ml), diluted with dichloromethane:water (1:1, 60ml), the organic
35 phase separated and solvent removed at reduced pressure to give 2-fluoroquinoline-4-carboxylic acid (0.02g) after trituration with dichloromethane/petroleum ether. ¹H NMR δ: 7.70 - 7.76 (2H, m), 7.85 - 7.96 (2H, m), 8.65 (1H, d), 14.24 (1H, brs). m/z (API⁺): 190 (MH⁺).

40 **Description 14: 4-Methylthio-3-acetylbenzoic acid (D14)**
Step 1: 3-Bromo-4-methylthiobenzoic acid methyl ester - Sodium thiomethoxide (0.42g) was added to a stirred solution of 3-bromo-4-fluorobenzoic acid methyl ester (1.0g) in dry dimethylformamide (20ml) and the mixture heated at 80°C for 1h. Solvent was removed at reduced pressure, the residue dissolved in ethyl acetate and washed with water. The

organic phase was dried (Na_2SO_4) and solvent removed at reduced pressure to give 3-bromo-4-methylthiobenzoic acid methyl ester (0.88g) as a colourless solid. m/z (API $^+$): 263 (MH $^+$).

Step 2: 3-Acetyl-4-methylthiobenzoic acid methyl ester - 3-Bromo-4-methylthiobenzoic acid methyl ester (0.86g), 1-ethoxyvinyl tributyl tin (1.39ml) and tetrakis triphenylphosphine palladium (IV) (0.15g) were combined in dioxan (50ml) and boiled for 24h. The mixture was cooled, water (10ml) and conc. hydrochloric acid (1ml) added and the mixture stirred at room temperature overnight. Solvent was removed at reduced pressure, the residue dissolved in ethyl acetate and filtered through celite. The filtrate was evaporated to dryness and the residue triturated with hexane to give 3-acetyl-4-methylthiobenzoic acid methyl ester (0.45g) as a yellow solid. m/z (API $^+$): 225 (MH $^+$).

Step 3: 3-Acetyl-4-methylthiobenzoic acid - 3-acetyl-4-methylthiobenzoic acid methyl ester (0.43g) in water:methanol (1:3, 290ml) containing sodium hydroxide (0.2g) was stirred for 6h. Methanol was removed at reduced pressure and the solution acidified with conc. hydrochloric acid to give 3-acetyl-4-methylthiobenzoic acid (0.32g) after filtration. m/z (API $^+$): 211 (MH $^+$).

The compound of D14 was used to prepare Example 7.

Description 15: 8-Fluoro-2-chloroquinoline-4-carboxylic acid (D15)

Step 1: 8-Fluoro-2-hydroxyquinoline-4-carboxylic acid - 8-Fluoroisatin (*D. Ing. Chim. (Brussels)*, 1982, 64(303), 3, 5-6) (13.27g) and malonic acid were combined in acetic acid (125 ml) and boiled for 20h. After cooling to room temperature a brown precipitate (3.3g) was separated by filtration. Filtrate was evaporated to dryness and the resulting solid triturated with ethyl acetate/diethyl ether to give a colourless residue (1.5g). The residual solid was compared with the material separated by filtration in ethanol (250ml) and the mixture boiled for 16h. Solvent volume was reduced to approximately 100ml and the precipitated colourless solid separated by filtration giving the title compound (1.15g). ^1H NMR δ : 6.95 (1H, s), 7.19 - 7.28 (1H, m), 7.45 - 7.52 (1H, m), 7.99 (1H, d, J = 8.3Hz), 12.09 (1H, brs).

Step 2: 8-Fluoro-2-chloroquinoline-4-carboxylic acid - The hydroxy acid of step 1 (0.31g) was suspended in phosphoryl chloride and the mixture boiled for 3.5h. After cooling, the mixture was added dropwise to ice cooled water and stirred for 3h. The precipitated product (0.267g) was collected by filtration washed with water and dried. m/z (API $^+$): 224, 226 (MH $^+$). ^1H NMR (CDCl_3) δ : 7.68 - 7.75 (2H, m), 7.97 (1H, s), 8.37 - 8.44 (1H, m), 14.15 (1H, brs).

35 **Description 16: 8-Fluoro-2-methoxyquinoline-4-carboxylic acid (D16)**

Step 1: 8-Fluoro-2-methoxyquinoline-4-carboxylic acid methyl ester
8-Fluoro-2-chloroquinoline-4-carboxylic acid (0.986g) suspended in dichloromethane (50ml) was treated with dimethylformamide (3 drops) and oxalyl chloride (0.76ml) and the mixture stirred for 2h. Solvent was removed at reduced pressure. The residue was dissolved in methanol (50ml) containing sodium methoxide (0.54g) and stirred for 16h. The solvent was removed at reduced pressure and the residue triturated with water. The precipitate was collected by filtration and column chromatographed (silica gel, 10 → 50% ethyl acetate/hexane) to give the title compound (0.184g) as a colourless solid. m/z (API $^+$):

236 (MH^+). 1H NMR ($CDCl_3$) δ : 4.02 (3H, s), 4.14 (3H, s), 7.36 - 7.41 (2H, m), 7.49 (1H, s), 8.37 - 8.41 (1H, m).

Step 2: 8-Fluoro-2-methoxyquinoline-4-carboxylic acid - 8-Fluoro-2-methoxyquinoline-4-carboxylic acid methyl ester (0.182g) in methanol (10ml) containing

5 2N sodium hydroxide (0.41ml) was stirred at room temperature for 16h. Solvent was removed at reduced pressure, dissolved in water, and adjusted to pH2 with 2N hydrochloric acid. The precipitated title compound (0.155g) was collected by filtration and dried. m/z (API^+): 222 (MH^+). 1H NMR δ : 4.02 (3H, s), 7.44 - 7.62 (3H, m), 8.31 (1H, d).

Description 17: 8-Fluoro-2-methylquinoline-4-carboxylic acid (D17)

10 7-Fluoroisatin (3.0g) was added to 20% sodium hydroxide (15.6ml) and stirred for 15min. Stirring was continued for 3h, solvent was removed at reduced pressure, the residue dissolved in water and acidified with 2N hydrochloric acid. The reaction was extracted with ethyl acetate (x 3), the combined organic extracts dried (Na_2SO_4) and solvent removed at reduced pressure. The residue was triturated with diethyl ether to give the title
15 compound (0.215g) as a pale yellow solid. 1H NMR δ : 2.75 (3H, s), 7.58 - 7.65 (2H, m), 7.93 (1H, s), 8.41 - 8.51 (1H, m), 13.95 (1H, brs).

Description 18: 8-Bromo-2-methylquinoline-4-carboxylic acid (D18)

A suspension of 7-bromoisatin (6.0g) in acetone (27ml) was treated with sodium hydroxide (4.6g) in water (23ml). The mixture was heated to reflux for 8h, cooled and solvent
20 reduced in volume at reduced pressure to approx. 25ml. The residual aqueous phase was acidified with conc. HCl, extracted with ethyl acetate, the organic phase dried ($MgSO_4$) and solvent removed at reduced pressure to give the title compound (7.2g) as a yellow solid. 1H NMR δ : 2.85 (3H, s), 7.40 (1H, m), 7.90 (1H, s), 8.05 (1H, dd, J = 1.2, 7.6Hz), 8.79 (1H, dd, J = 1.0, 8.5Hz).

25 **Description 19: 8-Ethyl-2-methylquinoline-4-carboxylic acid (D19)**

Step 1: 8-Bromo-2-methylquinoline-4-carboxylic acid ethyl ester - A stirred mixture of 8-bromo-2-methylquinoline-4-carboxylic acid (7.2g), ethanol (150ml) and conc. sulfuric acid (3ml) was boiled for 6h. After cooling to room temperature solvent was removed at reduced pressure, the residue treated with water and neutralised with solid potassium carbonate. The neutralised mixture was extracted with ethyl acetate, the extracts dried ($MgSO_4$) and solvent removed at reduced pressure. The residue was column chromatographed (silica gel (30% diethyl ether/60-80 petroleum ether) to give the ester (2.5g). m/z (API^+): 294, 296 (MH^+).

Step 2: 8-Ethyl-2-methylquinoline-4-carboxylic acid ethyl ester - 8-Bromo-2-

35 **methylquinoline-4-carboxylic acid ethyl ester (0.5g), lithium chloride (0.216g), tetraethyltin (0.435g) and bis(triphenylphosphine)palladium (II) chloride (0.05g) were combined in dimethylformamide (20ml) and heated at 100°C for 24h.** Solvent was removed at reduced pressure, the residue dissolved in dichloromethane and filtered. Solvent was removed at reduced pressure and the residue column chromatographed (silica gel, 5% diethyl ether/pentane) to give the title compound (0.215g). m/z (API^+): 244 (MH^+).

Step 3: 8-Ethyl-2-methylquinoline-4-carboxylic acid - 8-Ethyl-2-methylquinoline-4-carboxylic acid ethyl ester (0.205g) and 5N HCl combined and the solution boiled for 7h.

Solvent was removed at reduced pressure to give the title compound (0.195g) as a yellow solid. m/z (API⁺): 216 (MH⁺), 214 (API⁻) 214(M-H).

Description 20: 2,2,2-Tribromo-N-(8-fluoro-2-methyl-quinolin-4-yl)-acetamide (D20)

5 Tribromoacetyl chloride (6.05g) was added to a suspension of quinoline D3 (3.09g) and triethylamine (2.63ml) in dichloromethane (175ml). After 30 min the mixture was washed with water (x 2) and brine dried (Na₂SO₄) and solvent removed at reduced pressure to give the title compound (7.85g), after trituration with diethyl ether/pentane, as an orange/yellow solid. ¹H NMR (CDCl₃) δ: 2.88 (3H, s), 7.48 - 7.61 (3H, m), 8.25 (1H, s).

Description 21: 5-Amino-2-(4-methoxy-phenoxy)-benzoic acid methyl ester (D21)

10 **Step 1: 2-(4-Methoxy-phenoxy)-5-nitro-benzoic acid methyl ester** - 2-(4-Methoxy-phenoxy)-5-nitro-benzoic acid (2.5g), (DE 2058295) in methanol (75ml) containing conc. sulfuric acid (3 drops) was boiled for 16h. Solvent was removed at reduced pressure, the residue dissolved in ethyl acetate and washed with aqueous sodium hydrogen carbonate.

The organic phase was dried (Na₂SO₄) and solvent removed at reduced pressure to give 2-(4-methoxy-phenoxy)-5-nitro-benzoic acid methyl ester (2.50g). m/z (API⁺): 304 (MH⁺).

15 **Step 2: 5-Amino-2-(4-methoxy-phenoxy)-benzoic acid methyl ester** - The compound of step 1 (2.3g) in methanol (150ml) containing 10% Pd/C (0.5g) was hydrogenated under one atmosphere of hydrogen for 18h. The mixture was filtered (kieselguhr) and solvent removed from the filtrate under reduced pressure to give the title compound (2.0g) as a yellow oil. ¹H NMR (CDCl₃) δ: 3.69 (2H, brs), 3.77 (6H, s), 6.76 - 6.87 (6H, m), 7.19 (1H, d, J = 2.5Hz).

This compound was used to prepare Example 67

Description 22: 2,2,2-Tribromo-N-(6,8-difluoro-2-methyl-quinolin-4-yl)-acetamide (D22)

25 The title compound (1.66g) was prepared from quinoline D2 (0.75g) and tribromoacetyl chloride according to the method of D20. ¹H NMR (CDCl₃) δ: 3.08 (3H, s), 7.43 - 7.51 (2H, m), 8.37 (1H, s).

Description 23: 2,2,2-Tribromo-N-(5,8-difluoro-2-methyl-quinolin-4-yl)-acetamide (D23)

30 The title compound (1.83g) was prepared from quinoline D1 (0.75g) and tribromoacetyl chloride (0.84ml) according to the method of D20. ¹H NMR (CDCl₃) δ: 2.82 (3H, s), 7.13 - 7.24 (1H, m), 7.33 - 7.42 (1H, m), 8.53 (1H, s).

Description 24: 2,2,2-Trichloro-N-(6,8-difluoro-2-methyl-quinolin-4-yl)-acetamide (D24)

35 The title compound (1.83g) was prepared from quinoline D2 (0.60g) and trichloroacetyl chloride (0.38ml) according to the method of D20. ¹H NMR (CDCl₃) δ: 2.81 (3H, s), 7.16 - 7.21 (1H, m), 7.26 - 7.35 (1H, m), 8.15 (1H, s).

Description 25: 2,2,2-Trichloro-N-(8-fluoro-2-methyl-quinolin-4-yl)-acetamide (D25)

40 The title compound (0.64g) was prepared from quinoline D3 (0.35g) and trichloroacetyl chloride (0.24ml) according to the method of D20. ¹H NMR (CDCl₃) δ: 2.83 (3H, s), 7.16 - 7.21 (1H, m), 7.43 - 7.56 (3H, m), 8.18 (1H, s).

Description 26: 4-Methoxy-3-methylsulfanylmethyl-phenylamine (D26)

45 **Step 1: 1-Methoxy-2-methylsulfanylmethyl-4-nitro-benzene** - Sodium thiomethoxide (0.469g) was added to a solution of 2-methoxy-5-nitrobenzyl bromide (1.5g) in dimethylformamide (25ml). The mixture was stirred for 16h, solvent removed at reduced pressure and the residue dissolved in ethyl acetate and washed with water and brine, dried

(Na₂SO₄) and solvent removed at reduced pressure to give the title compound (1.2g) as a yellow solid

Step 2: 4-Methoxy-3-methylsulfanyl methyl-phenylamine - Sodium dithionite (3.264g) was added to a solution of 1-methoxy-2-methylsulfanyl methyl-4-nitro-benzene (0.8g), and sodium hydrogen carbonate (1.57g) in methanol:water (1:1, 200ml) and stirred at room temperature for 16h. Solvent was removed at reduced pressure, the residue partitioned between water and ethyl acetate, the organic phase separated, washed with brine dried (Na₂SO₄) and solvent removed at reduced pressure to give the title compound (0.23g) as a brown oil. m/z (API⁺): 184 (MH⁺).

10 The compound D26 was used to prepare Example 80.

Description 27: 5-Amino-2-ethyl-benzoic acid methyl ester (D27)

Step 1: 2-Ethyl-5-nitrobenzoic acid methyl ester - 2-Bromo-5-nitrobenzoic acid methyl ester (1.0g), lithium chloride (0.49g), tetraethyltin (0.96g) and bis(triphenylphosphine)-palladium(II)chloride (0.1g) were combined in dimethylformamide (20ml) and heated at 100°C for 8h. Solvent was removed at reduced pressure and the residue column chromatographed (silica gel, dichloromethane/petroleum ether 30:70) to give the title compound (0.45g). ¹H NMR (CDCl₃) δ: 1.28 (3H, t, J = 7.4Hz), 3.10 (2H, q, J = 7.4Hz), 3.96 (3H, s), 7.47 (1H, d, J = 8.5Hz), 8.27 (1H, dd, J = 2.5, 8.5Hz), 8.73 (1H, d, J = 2.5Hz).

20 **Step 2: 5-Amino-2-ethyl-benzoic acid methyl ester** - The compound of step 1 (0.45g) in methanol (50ml) containing 2N HCl (4ml) was shaken under a hydrogen atmosphere (25°C, 50psi) for 1h. The mixture was filtered (kieselguhr), the filtrate neutralised with sodium hydroxide (4ml, 2N) reduced to dryness, and the residue extracted with dichloromethane. The dichloromethane extracts were dried (MgSO₄) and solvent removed at reduced pressure to give the title compound (0.30g). ¹H NMR (CDCl₃) δ: 1.17 (3H, t, J = 7.4Hz), 2.85 (2H, q, J = 7.4Hz), 3.57 (2H, brs), 3.87 (3H, s), 6.76 (1H, dd, J = 2.5, 8.5Hz), 7.05 (1H, d, J = 8.5Hz), 7.17 (1H, d, J = 2.5Hz).

Compound D27 was used to prepare Example 68.

Description 28: 5-Amino-N-cyclopropylmethyl-2-ethyl-benzamide (D28)

30 **Step 1: 2-Ethyl-5-nitrobenzoic acid** Ethyl-5-nitrobenzoic acid methyl ester (1.0g) in methanol/2N sodium hydroxide (60ml, 1:1) was stirred for 1h at 60°C. Half the solvent was removed at reduced pressure, the residue diluted with water (20ml), washed with dichloromethane and the aqueous phase acidified with 2N HCl. The acidic phase was extracted with dichloromethane; the combined extracts dried (MgSO₄) and solvent removed at reduced pressure to give the title compound (0.45g) as a colourless solid. ¹H NMR (CDCl₃) δ: 1.32 (3H, t, J = 7.6Hz), 3.19 (2H, q, J = 7.6Hz), 7.52 (1H, d, J = 8.4Hz), 8.33 (1H, dd, J = 2.5, 8.4Hz), 8.90 (1H, d, J = 2.5Hz).

35 **Step 2: N-Cyclopropylmethyl-2-ethyl-5-nitro-benzamide** - 2-Ethyl-5-nitrobenzoic acid (0.40g), EDC.HCl (0.45g), cyclopropylmethylamine (0.17g) and hydroxybenzotriazole (0.04g) were combined in dimethylformamide (10ml) and stirred for 18h. Solvent was removed at reduced pressure, the residue dissolved in dichloromethane and washed with 2N HCl and water. The organic phase was dried (MgSO₄) and solvent removed at reduced pressure to give the title compound (0.4g). ¹H NMR (CDCl₃) δ: 0.31 (2H, m), 0.59 (2H, m),

1.09 (1H, m), 1.28 (3H, t, J = 7.6Hz), 2.92 (2H, m), 3.33 (2H, m), 5.97 (1H, brs), 7.45 (1H, d, J = 8.4Hz), 8.20 (2H, m).

5 **Step 3: 5-Amino-N-cyclopropylmethyl-2-ethyl-benzamide** - The title compound (0.32g) was prepared from N-cyclopropylmethyl-2-ethyl-5-nitro-benzamide (0.40g) according to the method of D21 step 2. ¹H NMR (CDCl₃) δ: 0.26 (2H, m), 0.54 (2H, m), 1.03 (1H, m), 1.18 (3H, t, J = 7.6Hz), 2.67 (2H, q, J = 7.6Hz), 3.28 (2H, m), 5.85 (1H, brs), 6.69 (2H, m), 7.03 (1H, d, J = 8.4Hz).

The compound of D28 was used to prepare the compound of Example 37.

10 **Description 29: 6-Amino-2-methylaminobenzoxazole (D29)**

15 **Step 1: 2-Methylamino-6-nitrobenzoxazole** - 2-Methylaminobenzoxazole (2.0g, Hetzheim, Annemarie; Schlaak, G.; Kerstan, Christa., *Pharmazie*, (1987), 42, 80) was added in portions to conc. nitric acid (15ml) at room temperature. Stirring was continued over 8h. The reaction mixture was poured onto crushed ice/sodium hydrogen carbonate with vigorous stirring. The precipitated title compound (1.76g) was collected by filtration and dried in vacuo at 40°C. m/z (API⁺): 194 (MH⁺).

20 **Step 2: 6-Amino-2-methylaminobenzoxazole** The title compound (1.31g) was prepared from 2-methylamino-6-nitrobenzoxazole (1.50g) according to the method of D21 step 2. ¹H NMR (CDCl₃) δ: 3.07 (3H, d, J = 3.4Hz), 6.52 (1H, dd, J = 2.1, 8.2Hz), 6.65 (1H, d, J = 2.1Hz), 7.15 (1H, d, J = 8.2Hz).

25 The compound of D29 was used to prepare the compound of Example 73.

20 **Description 30: (E)-3-(5-Amino-2-methoxy-phenyl)-N-methyl-acrylamide (D30).**

25 **Step 1: (E)-3-(5-Nitro-2-methoxy-phenyl)-N-methyl-acrylamide** - (E)-3-(2-Methoxy-5-nitro-phenyl)-acrylic acid (*Egypt. J. Pharm. Sci.*, (1996), 37, 71-84), (1.0g) in dimethylformamide (5ml) was treated with EDC.HCl (0.86g), N-hydroxybenzotriazole (0.1g) and methylamine (2M in tetrahydrofuran 3ml) and stirred for 18h. Solvent was removed at reduced pressure, the residue dissolved in dichloromethane, washed with 2N HCl, sodium hydrogen carbonate and brine. After drying (MgSO₄), solvent was removed at reduced pressure and the residue column chromatographed (silica gel, 5% methanol:dichloromethane) to give the title compound (0.75g). ¹H NMR δ: 2.71 (3H, d, J = 4.7Hz), 4.01 (3H, s), 6.71 (1H, d, J = 15.9Hz), 7.30 (1H, d, J = 9.2Hz), 7.62 (1H, d, J = 15.9Hz), 8.09 (1H, m), 8.25 (1H, dd, J = 2.8, 9.2Hz), 8.36 (1H, d, J = 2.8Hz).

30 **Step 2: (E)-3-(5-Amino-2-methoxy-phenyl)-N-methyl-acrylamide** - (E)-3-(5-Nitro-2-methoxy-phenyl)-N-methyl-acrylamide (0.75g) and sodium sulphide (1.0g) were combined in 1,4-dioxan/water (1:1, 20ml) and warmed at 80°C for 3h. Solvent was removed at reduced pressure, the residue extracted with 10% methanol/dichloromethane and the extract filtered. The filtrate was evaporated to dryness and the residue column chromatographed (silica gel, 5% methanol:dichloromethane) to give the title compound (0.50g). ¹H NMR δ: 2.68 (3H, d, J = 4.8Hz), 3.71 (3H, s), 6.44 (1H, d, J = 15.9Hz), 6.60 (1H, dd, J = 2.8, 9.2Hz), 6.73 (1H, d, J = 2.8Hz), 6.78 (1H, d, J = 9.2Hz), 7.57 (1H, d, J = 15.9Hz), 8.00 (1H, m).

35 The compound of D30 was used to prepare the compound of Example 38.

40 **Description 31: 3-Chloro-4-methanesulfonyloxybenzoic acid (D31)**

Sodium hydroxide (1.67g) and 3-chloro-4-hydroxybenzoic acid (3.0g) in water (30ml) was stirred until dissolution was complete. Methanesulfonic anhydride (3.33g) in dichloromethane (15ml) was added with cooling (ice bath) and the mixture stirred for 48h. The organic phase was separated and the aqueous phase acidified with conc. HCl. The precipitated colourless solid was separated by filtration, washed with water and recrystallised from methanol to give the title compound (1.85g) as a colourless solid. m/z (API⁺): 249, 251 (MH⁺).

5 The compound of D31 was used for the preparation of Example 83.

10 **Description 32: 5-Amino-N-cyclopropylmethyl-2-methoxy-benzamide**
Step 1: N-cyclopropylmethyl-2-methoxy-5-nitrobenzamide - A solution of 2-methoxy-5-nitrobenzoic acid (4.9g) (*Rec. Trav. Chim. Pays-Bas*, 1936, 737) and cyclopropylmethylamine (1.75g) in dimethylformamide was treated with N-hydroxybenzotriazole (0.2g) and EDC.HCl (4.74g). The mixture was stirred for 24h. Saturated sodium hydrogen carbonate was added, the mixture stirred for 3h and the precipitate collected as the title compound (6.95g). m/z (API⁺): 251 (MH⁺).

15 Step 2: 5-Amino-N-cyclopropylmethyl-2-methoxy-benzamide - (2.57g) was prepared from N-cyclopropylmethyl-2-methoxy-5-nitrobenzamide (3.6g) according to the method of D21 step 2. m/z (API⁺): 231 (MH⁺). ¹H NMR (CDCl₃) δ: 0.26 (2H, m), 0.51 - 0.55 (2H, m), 3.33 (1H, m), 3.55 (2H, brs), 3.90 (3H, s), 6.79 (2H, m), 7.56 (1H, dd, J = 0.5, 2.8Hz), 8.08 (1H, brs).

20 The compound of D32 was used for the preparation of Examples 32, 39 and 57.
4-Amino-8-chloro-2-methylquinoline is a known compound used for the preparation of example 45, *Indian J. Chem., Sect. B* (1978), 16B(4), 329.

25 4-Amino-2,8-dimethylquinoline is a known compound used for the preparation of example 44, WO 92/22533.

4-Amino-2,6-dimethylquinoline is a known compound used for the preparation of example 42, *Dokl. Bolg. Akad. Nauk* (1977), 30(12), 1725-8.

30 4-Amino-2-N,N-dimethylaminoquinoline is a known compound used for the preparation of example 65 *Arch. Pharm. (Weinheim, Ger.)* (1986), 319(4), 347-54.


5-Amino-2-ethoxy-benzoic acid ethyl ester is a known compound used for the preparation of example 71 *Prakt. Akad. Athenon* (1981), 55(A-B), 211-33.

35 6-Amino-2-methylbenzothiazole is a known compound used for the preparation of example 72 *Synthesis*, (1978), (5), 363.

4-Amino-2-methylquinoline is a commercially available compound used for the preparation of examples 6 and 54.

2-Methoxy-4-quinoline carboxylic acid is a known compound used for the preparation of examples 36 and 79 WO 92/12150.


Example 1: 1-(2-Methylbenzoxazol-6-yl)-3-(2-methylquinolin-4-yl)urea



A slurry of 4-amino-2-methylquinoline (0.158g) in dichloromethane (10ml) was added to solution of carbonyl diimidazole (0.162g) in dichloromethane (5ml). The mixture was stirred for 2.5h, solvent removed at reduced pressure and the residue dissolved in

5 dimethylformamide (15ml). 6-Amino-2-methylbenzoxazole (0.148g) (*Res. Inst. Drugs, Modra, Slovakia. Collect. Czech. Chem. Commun.* (1996), **61**, 371-380) was added and the mixture warmed to 100°C for 1h. Solvent was removed at reduced pressure and triturated with diethyl ether and methanol to give the title compound (0.035g) as a colourless solid.
 10 ^1H NMR δ : 2.59 (3H, s), 2.60 (3H, s), 7.24 (1H, dd, $J = 1.9, 8.5\text{Hz}$), 7.58 - 7.63 (2H, m),
 7.73 (1H, t, $J = 7.2\text{Hz}$), 7.89 (1H, d, $J = 7.7\text{Hz}$), 8.06 (1H, d, $J = 1.8\text{Hz}$), 8.13 - 8.15 (2H, m), 9.22 (1H, brs), 9.55 (1H, brs). m/z (API $^+$): 333 (MH $^+$).


Example 2: 1-(4-Dimethylaminophenyl)-3-(2-methylquinolin-4-yl)urea



4-N,N-Dimethylaminophenyl isocyanate (0.162g) was added to a stirred solution of 4-

15 amino-2-methylquinoline (0.158g) in dichloromethane (20ml) containing 4-N,N-dimethylaminopyridine (2mg). The mixture was stirred for 16h under argon, diluted with diethyl ether (20ml) and the precipitated solid collected by filtration and washed with diethyl ether to give the title compound (0.146g) as a colourless solid. ^1H NMR δ : 2.61 (3H, s), 2.86 (6H, s); 6.74 (2H, d, $J = 9.0\text{Hz}$), 7.33 (2H, d, $J = 9.0\text{Hz}$), 7.58 (1H, t, $J = 7.0\text{Hz}$),
 20 7.71 (1H, t, $J = 7.6\text{Hz}$), 7.87 (1H, d, $J = 8.3\text{Hz}$), 8.13 (1H, d, $J = 8.5\text{Hz}$), 8.15 (1H, s), 8.98 (1H, s), 9.04 (1H, s).

Example 3: 1-(2-Methylbenzoxazol-6-yl)-3-(2-chloroquinolin-4-yl)urea




2-Chloro-4-chlorocarbonylquinoline (0.5g), prepared by standard methods from 2-

25 chloroquinoline-4-carboxylic acid, was added to sodium azide in aqueous dioxan (2.1ml 1:3) at 0°C. Acetone was then added and the mixture stirred for 16h. Water (10ml) was


added, the precipitated solid collected by filtration and air dried to give 2-chloroquinoline-4-carbonyl azide (0.455g). The azide (0.232g) in toluene (10ml) was warmed from room temperature to 75°C and then heating continued for 1h. After cooling to room temperature 6-amino-2-methylbenzoxazole (0.148g) in dichloromethane (15ml) containing 4-N,N-dimethylaminopyridine (20mg) was added and the mixture stirred for 16h. The precipitated solid was separated by filtration to give a solid (0.25g). Column chromatography (silica gel, dichloromethane/methanol/ammonia mixtures) gave the title compound (0.072g). ¹H NMR δ: 5.26 (3H, s), 7.25 (1H, d, J = 8.5Hz), 7.61 (1H, d, J = 8.5Hz), 7.73 (1H, t, J = 7.0Hz), 7.84 (1H, t, J = 6.7Hz), 7.91 (1H, d, J = 8.0Hz), 8.05 (1H, s), 8.20 (1H, d, J = 8.25Hz), 8.28 (1H, s), 9.49 (1H, s), 9.61 (1H, s). m/z (API⁺): 353, 355(MH⁺).

Example 4: 1-(4-N,N-Dimethylaminophenyl)-3-(2-chloroquinolin-4-yl)urea



From 2-chloroquinoline-4-carbonyl azide (1.5g), (see example 3) and 4-N,N-dimethylphenylenediamine (0.88g) the title compound was prepared according to the method of example 3. ¹H NMR δ: 2.87 (6H, s), 6.75 (2H, d, J = 9.0Hz), 7.33 (2H, d, J = 9.0Hz), 7.67 - 7.99 (4H, m), 8.17 - 8.31 (3H, m), 9.05 (1H, s), 9.34 (1H, s). m/z (API⁺): 341, 343 (MH⁺).


Example 5: 1-(3-Butyryl-4-methoxyphenyl)-3-(5,8-difluoroquinolin-4-yl)urea



To a suspension of 3-butyryl-4-methoxybenzoic acid (0.111g) in toluene (4ml), triethylamine (0.21ml) and diphenylphosphoryl azide (0.11ml) were added. The mixture was stirred for 16h, quinoline D1 (0.097g) added and mixture boiled for 4h. Solvent was removed at reduced pressure and the residue column chromatographed (silica gel, 0 - 10% methanol containing 1% ammonia:dichloromethane) to give the title compound (0.02g). ¹H NMR δ: 0.74 (3H, m), 1.42 (2H, m), 2.45 (3H, s), 2.74 (2H, t, J = 7.2Hz), 3.70 (3H, s), 6.99 (1H, d, J = 8.8Hz), 7.17 (1H, m), 7.33 - 7.53 (3H, m), 8.15 (1H, s), 8.67 (1H, d, J = 15Hz), 9.78 (1H, s). m/z (API⁺): 414 (MH⁺).

Examples 6 - 20, 64, 83


Were prepared by standard methods illustrated by Example 5 using the appropriate aminoquinoline and carboxylic acid.







e.g.	Quinoline used	R	Ar	yield	MS (API+)
6	-	H	3-Br, 4-SMeC ₆ H ₃	22%	MH+ 402, 404
7	D2	6,8-diF	4-MeS, 3-COMe-C ₆ H ₃	2.8%	MH+ 402
8	D3	8-F	4-MeO, 3-CNC ₆ H ₃	84%	MH+ 351
9	D1	5,8-diF	4-MeO, 3-COMeC ₆ H ₃	52%	MH+ 386
10	D1	5,8-diF	4-Cl, 3-COMeC ₆ H ₃	45%	MH+ 390
11	D3	8-F		56%	MH+ 351
12	D2	6,8-diF		5%	MH+369
13	D3	8-F	4-MeO, 3-COPrC ₆ H ₃	38%	MH+ 396
14	D2	6,8-diF	3-Cl, 4-OEtC ₆ H ₃	22%	MH+ 393
15	D2	6,8-diF	3-MeO, 4-MeC ₆ H ₃	2%	MH+ 358
16	D1	5,8-diF		5%	MH+ 369
17	D4	5,6-diF		7%	MH+ 369
18	D5	5,7-diF		10%	MH+ 369
19	D6	6-Cl		18%	MH+ 366, 368
20	D7	7,8-diF		3%	MH+ 369
64	D1	5,8-diF		32%	MH+ 422
83	D1	5,8-diF		37%	MH+ 442

¹H NMR spectra were consistent with the structures in the table.

Examples 21 - 38, 79 were prepared by standard methods illustrated by Example 5 using the appropriate quinoline carboxylic acid and aniline.




e.g.	Quinoline	R ²	R ³	Ar	yield	MS (API+)
21	D19	Me	8-Et	4-NMe ₂ C ₆ H ₄	14%	MH+ 349
22	D17	Me	8-F		83%	MH+ 364
23	D17	Me	8-F		51%	MH+ 350
24	D17	Me	8-F	4-CO ₂ Et-C ₆ H ₄	32%	MH+ 368
25	D17	Me	8-F		25%	MH+ 407
26	D13	F	H		30%	MH+ 337
27	D13	F	H	4-NMe ₂ C ₆ H ₄	8%	MH+ 324
28	D12	SMe	H		80%	MH+ 365
29	D15	Cl	8-F		46%	MH+ 404
30	D15	Cl	8-F	4-NMe ₂ C ₆ H ₄	44%	MH+ 359
31	D15	Cl	8-F		61%	MH+ 371
32	D16	OMe	8-F		55%	MH+ 439
33	D16	OMe	8-F		93%	MH+ 380
34	D16	OMe	8-F		54%	MH+ 400
35	D16	OMe	8-F	4-NMe ₂ C ₆ H ₄	28%	MH+ 355

36	known	OMe	H		66%	MH+ 349
37	D17	Me	8-F		95%	MH+ 421
38	D17	Me	8-F		43%	MH+409
79	known	OMe	H		40%	MH+ 382

¹H NMR spectra were consistent with the structures in the table


Example 39: N-Cyclopropylmethyl-5-[3-(8-fluoro-2-methyl-quinolin-4-yl)-ureido]-2-methoxy-benzamide hydrochloride



5

The title compound (0.265g) as the free base was prepared from acid D17 (0.205g) and 5-amino-N-cyclopropylmethyl-2-methoxy-benzamide (0.22g) according to the method of example 5. The hydrochloride salt (0.095g) was prepared from the free base (0.10g) by dissolving in methanol and treating with ethereal HCl. m/z (API): 423 (MH⁺). ¹H NMR (CDCl₃) δ: 0.24 - 0.26 (2H, m), 0.41 - 0.46 (2H, m), 0.99 - 1.10 (1h, m), 2.82 (3H, s), 3.19 (1H, t, J = 6.5Hz), 3.89 (3H, s), 7.16 (1H, d, J = 9.1Hz), 7.67 (1H, dd, J = 2.8, 8.9Hz), 7.74 (1H, m), 7.84 - 7.92 (1H, m), 7.95 (1H, d), 8.25 (1H, t), 8.60 (1H, s), 8.95 (1H, brd), 11.04 (1H, brs), 11.17 (1H, brs).

Examples 40 - 49, 65, 82
15 Were prepared by standard methods illustrated by either Example 2 or below for Example 40 using the appropriate aminoquinoline and isocyanate.



20 The amine D1 (0.097g) was added to sodium hydride (60% suspension in oil, 0.024g) in dimethylformamide (5ml). After 1h gas evolution had ceased and 4-dimethylaminophenylisocyanate (0.081g) added and the mixture stirred for 2h. Water was


added to the mixture and the precipitated product collected by filtration and washed with water and diethyl ether to give the desired product (0.14g).

e.g.	Quinoline used	method	R	R ¹	yield	MS (API+)
40	D1	40	Me	5,8-diF	80%	MH+ 357
41	D7	40	Me	7,8-diF	73%	MH+ 357
42	known	2	Me	6-Me	30%	MH+ 335
43	D4	40	Me	6,7-diF	33%	MH+ 357
44	known	2	Me	8-Me	66%	MH+ 335
45	known	2	Me	8-Cl	53%	MH+ 355
46	D11	40	Me	8-Cl-7-Me	23%	MH+ 369, 371
47	D8	2	Me	6-F	24%	MH+ 339
48	D11	2	Me	8-CH:CH ₂	7%	MH+ 347
49	D4	40	Me	5,6-diF	38%	MH+ 357
65	known	2	NMe ₂	H	34%	MH+ 350
82	D9	2	Me	8-Br	32%	MH+ 399, 401

¹H NMR spectra were consistent with the structures in the table


5

Example 50: 1-(4-Acetyl-phenyl)-3-(8-fluoro-2-methyl-quinolin-4-yl)-urea



The title compound (0.60g) was prepared from quinoline D3 (0.40g) and 4-acetylphenyl isocyanate (0.367g) according to the method of Example 2. m/z (API⁺): 338 (MH⁺). ¹H NMR δ: 2.54 (3H, s), 2.64 (3H, s), 7.54 - 7.61 (1H, m), 7.66 (1H, d, J = 5.5Hz), 7.96 (1H, m), 8.22 (1H, s), 9.30 (1H, s), 9.68 (1H, s).


Example 51: 1-(6,8-Difluoro-2-methyl-quinolin-4-yl)-3-(4-dimethylamino-phenyl)-urea



The title compound (0.08g) was prepared from quinoline D2 (0.19g) and 4-dimethylaminophenyl isocyanate (0.16g) according to the method of Example 40. m/z (API⁺): 357 (MH⁺). ¹H NMR δ: 2.60 (3H, s), 2.82 (6H, s), 6.74 (2H, d, J = 9.0Hz), 7.33 (2H, d, J = 9.0Hz), 7.65 - 7.80 (2H, m), 8.25 (1H, s), 8.89 (1H, s), 8.99 (1H, s).

Examples 52 - 55, 80

Were prepared by standard methods illustrated by Example 1 from the appropriate aminoquinoline and aniline.




10

e.g.	Quinoline used	R	Ar	yield	MS (API ⁺)
52	D3	8-F	3-MeO, 5-CO ₂ MeC ₆ H ₃	7%	MH ⁺ 384
53	D2	6,8-diF	4-MeO, 3-MeOCH ₂ C ₆ H ₃	2%	MH ⁺ 388
54	known	H		20%	MH ⁺ 319
55	D2	6,8-diF	4-MeO, 3-MeC ₆ H ₃	26%	MH ⁺ 358
80	D2	6,8-diF		6%	MH ⁺ 404


¹H NMR spectra were consistent with the structures in the table

Example 56: 1-(5,8-Difluoro-2-methyl-quinolin-4-yl)-3-(5-oxo-5,6,7,8-tetrahydro-naphthalen-2-yl)-urea



The title compound (0.23g) was prepared according to the method of Example 1 from quinoline D1 (0.42g) and 6-amino-1,2,3,4-tetrahydronaphthalen-1-one (0.35g). m/z (API⁺): 382 (MH⁺). ¹H NMR δ: 1.09 - 2.07 (2H, m), 2.55 (2H, m), 2.64 (3H, s), 2.91 (2H, m), 7.32 - 7.42 (2H, m), 7.52 - 7.58 (2H, m), 7.85 (1H, d, J = 5.3Hz), 8.29 (1H, s), 9.00 (1H, brs), 10.26 (1H, brs).

Example 57: N-Cyclopropylmethyl-5-[3-(5,8-difluoro-2-methyl-quinolin-4-yl)-ureido]-2-methoxy-benzamide




5 The title compound (0.11g) was prepared according to the method of Example 1 from quinoline D1 (0.22g) and 5-amino-N-cyclopropylmethyl-2-methoxy-benzamide (0.23g). m/z (API⁺): 441 (MH⁺). ¹H NMR δ: 0.25 (2H, m) < 0.44 (2H, m), 1.05 (1H, m), 2.62 (3H, s), 3.19 (2H, t, J = 3.8Hz), 3.89 (3H, s), 7.13 (1H, d, J = 5.8Hz), 7.31 - 7.35 (1H, m), 7.52 - 7.56 (1H, m), 7.69 (1H, dd, J = 2, 5.5Hz), 7.88 (1H, d, J = 2Hz), 8.26 (1H, t, J = 3.5Hz), 8.84 (1H, brd), 9.95 (1H, brs)

10 15

Examples 58 – 63

Were prepared by a standard method illustrated below for Example 58 from the appropriate ketone.









20 **Example 58: 1-(8-Fluoro-2-methoxy-quinolin-4-yl)-3-(5-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)-urea**

The quinoline of Example 33 (0.091g) was suspended in methanol (10ml). Sodium borohydride (0.064g) was added and the mixture stirred for 3h. Dichloromethane (5ml) was added to assist solubilisation of material and stirring continued for a further 2h.

Solvent was removed at reduced pressure, the residue partitioned between dichloromethane/water, the organic phase dried (MgSO_4), solvent removed at reduced pressure and the residue column chromatographed (silica gel, 0 - 10% [9:1 methanol:ammonia] in dichloromethane) to give the title compound (0.009g). ^1H NMR δ :

5 1.69 (2H, m), 2.67 (2H, m), 3.98 (3H, s), 4.53 (1H, m), 5.02 (1H, d, $J = 5.7\text{Hz}$), 7.23 - 7.25 (2H, m), 7.34 (1H, m), 7.44 - 7.59 (2H, m), 7.80 (1H, s), 7.90 (1H, d, $J = 8.1\text{Hz}$), 9.17 (1H, brs), 9.24 (1H, brs).


e.g.	Ketone	R2	R3	Ar	yield	MS (API)
58	e.g. 33	OMe	8-F		10%	MH+ 382
59	e.g. 22	Me	8-F		60%	MH+ 366
60	e.g. 23	Me	8-F		79%	MH+ 352
61	e.g. 13	Me	8-F		74%	MH+ 398
62	e.g. 56	Me	5,8-diF		9%	MH+ 384
63	e.g. 50	Me	8-F		76%	MH+ 340

^1H NMR spectra were consistent with the structures in the table

10

Examples 66 - 74

Were prepared by a standard method illustrated below for Example 66.



A mixture of the trichlorocetamide D24 (0.17g) DBU (0.076g) and 6-aminoindole (*J. Amer. Chem. Soc.* 1954, **76**, 5149) (0.066g) were combined in DMSO (5ml) and warmed to 80°C for 1h and at 110°C for 4h. After cooling the reaction mixture was diluted with ethyl acetate, washed with water (x 3), dried (Na_2SO_4) and solvent removed at reduced pressure. The residue was column chromatographed (silica gel, dichloromethane - 4% methanol/dichloromethane) to give after combining appropriate fractions and converting to

the hydrochloride salt the title compound (0.01g). (Method A). m/z (API⁺): 353 (MH⁺).

¹H NMR δ: 2.79 (3H, s), 6.39 (1H, m), 7.03 (1H, dd, J = 1.8, 8.5Hz), 7.30 (1H, m), 7.49 (1H, d, J = 8.5Hz), 7.86 (1H, s), 8.07 (1H, t), 8.58 (2H, m), 10.41 (2H, m), 11.07 (1H, s).

Alternatively instead of using DMSO as solvent DMSO containing pyridine (5% by


5 volume) can be used (Method B)

e.g.	Acetamide	Method	R	Ar	yield	MS (API ⁺)
66	D24	A	6,8-diF		5	MH+ 353
67	D20	B	8-F		7	MH+ 476
68	D20	B	8-F		4	MH+ 382
69	D22	B	6,8-diF		32	MH+ 402
70	D20	B	8-F		31	MH+ 384
71	D20	B	8-F		29	MH+ 412
72	D24	A	6,8-diF		4	MH+ 385
73	D25	A	8-F		6	MH+ 366
74	D23	B	5,8-diF		12	MH+ 425

¹H NMR spectra were consistent with the structures in the table


Example 75: 1-(3-Chloro-4-methoxy-phenyl)-3-(5,8-difluoro-2-methyl-quinolin-4-yl)-urea

10



The title compound (0.005g) was prepared according to the method of Example 66 from acetamide D23 (0.118g) and 3-chloro-4-methoxyaniline (0.039g) but using pyridine as solvent. m/z (API⁺): 378 (MH⁺). ¹H NMR δ: 2.62 (3H, s), 3.83 (3H, s), 7.13 (1H, d, J = 9.0Hz), 7.28 - 7.40 (2H, m), 7.50 - 7.60 (1H, m), 7.74 (1H, d, J = 2.6Hz), 8.29 (1H, s), 8.86 (1H, d), 9.93 (1H, s).

5 9. Examples 76 - 78, 81
Were prepared by a standard method illustrated below for Example 76, by treating the appropriate ester with the corresponding primary amine



10 A mixture the compound of example 29 (0.02g) and cyclopropylmethylamine (2ml) were stood at room temperature for 72h. Solvent was removed at reduced pressure and the residue triturated with ethyl acetate/diethyl ether to give the title compound. m/z (API⁺): 443, 445 (MH⁺). ¹H NMR δ: 0.26 (2H, m), 0.41 - 0.46 (2H, m), 1.05 (1H, m), 3.19 (2H, t, J = 6.2Hz), 3.89 (3H, s), 7.15 (1H, d, J = 9.0Hz), 7.65 - 7.73 (3H, m), 7.87 (1H, d, J = 2.7Hz), 8.09 (1H, m), 8.29 (1H, m), 8.35 (1H, s), 9.57 (1H, s).

e.g.	ester e.g.	R2	R3	Ar	yield	MS (API ⁺)
76	29	Cl	8-F		59%	MH+ 443, 445
77	71	Me	8-F		30%	MH+ 437
78	69	Me	6,8-diF		55%	MH+ 441
81	79	OMe	H		48%	MH+ 395

¹H NMR spectra were consistent with the structures in the table

Determination of Orexin-1 Receptor Antagonist Activity

The orexin-1 receptor antagonist activity of the compounds of formula (I) was determined

5 in accordance with the following experimental method.

Experimental Method

HEK293 cells expressing the human orexin-1 receptor were grown in cell medium (MEM medium with Earl's salts) containing 2 mM L-Glutamine, 0.4 mg/mL G418 Sulfate from GIBCO BRL and 10% heat inactivated fetal calf serum from Gibco BRL. The cells were

10 seeded at 20,000 cells/100 µl/well into 96-well black clear bottom sterile plates from Costar which had been pre-coated with 10 µg/well of poly-L-lysine from SIGMA. The seeded plates were incubated overnight at 37°C in 5% CO₂.

Agonists were prepared as 1 mM stocks in water:DMSO (1:1). EC₅₀ values (the concentration required to produce 50% maximal response) were estimated using 11x half

15 log unit dilutions (Biomek 2000, Beckman) in Tyrode's buffer containing probenecid (10 mM HEPES with 145mM NaCl, 10mM glucose, 2.5 mM KCl, 1.5 mM CaCl₂, 1.2 mM MgCl₂ and 2.5mM probenecid; pH7.4). Antagonists were prepared as 10 mM stocks in DMSO (100%). Antagonist IC₅₀ values (the concentration of compound needed to inhibit 50% of the agonist response) were determined against 3.0 nM human orexin-A using 11x

20 half log unit dilutions in Tyrode's buffer containing 10% DMSO and probenecid.

On the day of assay 50 µl of cell medium containing probenecid (Sigma) and Fluo3AM (Texas Fluorescence Laboratories) was added (Quadra, Tomtec) to each well to give final concentrations of 2.5 mM and 4 µM, respectively. The 96-well plates were incubated for 90 min at 37°C in 5% CO₂. The loading solution containing dye was then aspirated and

25 cells were washed with 4x150 µl Tyrode's buffer containing probenecid and 0.1% gelatin (Denley Cell Wash). The volume of buffer left in each well was 125 µl. Antagonist or buffer (25 µl) was added (Quadra) the cell plates gently shaken and incubated at 37°C in 5% CO₂ for 30 min. Cell plates were then transferred to the Fluorescent Imaging Plate Reader (FLIPR, Molecular Devices) instrument and maintained at 37°C in humidified air.

30 Prior to drug addition a single image of the cell plate was taken (signal test), to evaluate dye loading consistency. The run protocol used 60 images taken at 1 second intervals followed by a further 24 images at 5 second intervals. Agonists were added (by the FLIPR) after 20 sec (during continuous reading). From each well, peak fluorescence was determined over the whole assay period and the mean of readings 1-19 inclusive was subtracted from this

35 figure. The peak increase in fluorescence was plotted against compound concentration and iteratively curve fitted using a four parameter logistic fit (as described by Bowen and Jerman, 1995, *TiPS*, 16, 413-417) to generate a concentration effect value. Antagonist K_b values were calculated using the equation:


$$K_b = IC_{50}/(1+([3/EC_{50}]))$$

40 where EC₅₀ was the potency of human orexin-A determined in the assay (in nM terms) and IC₅₀ is expressed in molar terms.

As an illustration of the activity of the compounds of formula (I), the compounds of Examples 1 and 2 each had a pK_b > 6.0 in this assay.

CLAIMS

1. A compound of formula (I):



5

in which:

Z represents oxygen or sulfur;

R¹ represents (C₁₋₆)alkyl, (C₂₋₆)alkenyl or (C₁₋₆)alkoxy, any of which may be optionally substituted; halogen, R⁸CO- or NR⁹R¹⁰CO-;

10 R², R³, R⁴, R⁵ and R⁶ independently represent (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkoxy or (C₁₋₆)alkylthio, any of which may be optionally substituted; hydrogen, halogen, nitro, cyano, aryloxy, aryl(C₁₋₆)alkyloxy, aryl(C₁₋₆)alkyl, R⁸CO-, R⁸SO₂NH-, R⁸SO₂O-, R⁸CON(R¹¹)-, NR⁹R¹⁰-, NR⁹R¹⁰CO-, -COOR⁹, R¹¹C(=NOR⁸), heterocyclyl or heterocyclyl(C₁₋₆)alkyl; or an adjacent pair of R², R³, R⁴, R⁵ and R⁶ together with the carbon atoms to which they are attached form an optionally substituted carbocyclic or heterocyclic ring;

15 R⁷ is (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkoxy or (C₁₋₆)alkylthio, any of which may be optionally substituted; halogen, hydroxy, nitro, cyano, NR⁹R¹⁰-, NR⁹R¹⁰CO-, N₃, -OCOR⁹ or R⁸CON(R¹¹)-;

20 R⁸ is (C₁₋₆)alkyl, (C₂₋₆)alkenyl, heterocyclyl, heterocyclyl(C₁₋₆)alkyl, heterocyclyl(C₂₋₆)alkenyl, aryl, aryl(C₁₋₆)alkyl or aryl(C₂₋₆)alkenyl, any of which maybe optionally substituted;

R⁹ and R¹⁰ independently represent hydrogen, (C₁₋₆)alkyl, (C₂₋₆)alkenyl, heterocyclyl, heterocyclyl(C₁₋₆)alkyl, aryl or aryl(C₁₋₆)alkyl, any of which maybe optionally substituted;

R¹¹ is hydrogen or (C₁₋₆)alkyl; and

n is 0, 1, 2, or 3;

25 or a pharmaceutically acceptable salt thereof.

provided that the compound is not:

- a) N-(2-methyl-4-quinolinyl)-N'-(3-(trifluoromethyl)phenyl)urea;
- b) N-(4-methoxyphenyl)-N'-(2-methyl-4-quinolinyl)urea;
- c) N-[3-(dimethylamino)phenyl]-N'-(2-methyl-4-quinolinyl)urea;
- 30 d) N-(3-methoxyphenyl)-N'-(2-methyl-4-quinolinyl)urea;
- e) ethyl 3-[[[(2-methyl-4-quinolinyl)amino]carbonyl]amino]benzoate;
- f) N-[3-hydroxyphenyl]-N'-(2-methyl-4-quinolinyl)urea;
- g) N-[2,3-dichlorophenyl]-N'-(2-methyl-4-quinolinyl)urea;
- h) N-benzo[b]thien-5-yl-N'-(2-methyl-4-quinolinyl)urea;

- i) N-(1-methyl-1H-indol-5-yl)-N'-(2-methyl-4-quinolinyl)urea;
- j) N-(2-methyl-4-quinolinyl)-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)urea;
- k) N-(2-methyl-4-quinolinyl)-N'-(3,4,5-trimethoxyphenyl)urea;
- l) N-(2-methylphenyl)-N'-(2-methyl-4-quinolinyl)urea;
- 5 m) N-(4-methylphenyl)-N'-(2-methyl-4-quinolinyl)urea;
- n) N-(3,5-dimethylphenyl)-N'-(2-methyl-4-quinolinyl)urea;
- o) N-(4-chlorophenyl)-N'-(2-methyl-4-quinolinyl)urea;
- p) N-(2-methyl-4-quinolinyl)-N'-[3-(trifluoromethyl)phenyl]urea;
- q) N-(2-methoxyphenyl)-N'-(2-methyl-4-quinolinyl)urea;
- 10 r) N-(2-methyl-4-quinolinyl)-N'-phenylurea;
- s) N-(3,4-dimethylphenyl)-N'-(2-methyl-4-quinolinyl)urea;
- t) N-(4-methyl-2-nitrophenyl)-N'-(2-methyl-4-quinolinyl)urea;
- u) N-(3-chloro-4-methylphenyl)-N'-(2-methyl-4-quinolinyl)urea;
- v) N-(5-chloro-2-methoxyphenyl)-N'-(2-methyl-4-quinolinyl)urea;
- 15 w) 1-(6-amino-2-methyl-4-quinolinyl)-3-(o-nitrophenyl)urea; or
- x) N-(1,2-dihydro-6-methyl-2-oxo-4-quinolinyl)-N'-phenylthiourea.

2. A compound according to claim 1 in which Z represents oxygen.


20 3. A compound according to claim 1 or 2 in which n is 1 or 2.

4. A compound according to any one of the preceding claims in which R² to R⁶ independently represent hydrogen, R⁸CO-, NR⁹R¹⁰CO-, halogen, (C₁₋₆)alkoxy, (C₁₋₆)alkylthio, or NR⁹R¹⁰, and at least one of R² to R⁶ is other than hydrogen; or an adjacent pair of R² to R⁶ together with the carbon atoms to which they are attached form an optionally substituted 5- to 25 7-membered carbocyclic or heterocyclic ring.


5. A compound according to any one of the preceding claims in which R², R⁵ and R⁶ represent hydrogen.

30 6. A compound according to any one of claims 1 to 4 in which R², R⁴ and R⁶ represent hydrogen.

7. A process for the preparation of a compound of formula (I) as defined in any one of 35 the preceding claims or a salt thereof which comprises coupling a compound of formula (II):




with a compound of formula (III):



5 where A and B are appropriate functional groups to form the -NHCONH- or -NHCSNH- moiety when coupled; n is as defined in formula (I); and R¹ to R⁷ are R¹ to R⁷ as defined in formula (I) or groups convertible thereto; and thereafter optionally and as necessary and in any appropriate order, converting any R¹ to R⁷ when other than R¹ to R⁷ respectively to R¹ to R⁷, and/or forming a pharmaceutically acceptable salt thereof.

10 8. A compound library comprising at least 2 compounds of formula (I) as defined in any one of claims 1 to 6, or pharmaceutically acceptable salts thereof.

9. A compound of formula (II):



15 wherein A is -NH₂, -CON₃, -CO₂H, -N=C=O, -N=C=S, -NHCOL, halogen or -NHCOCBr₃, L is a leaving group, n is as defined in formula (I) and R¹ and R⁷ are R¹ and R⁷ as defined in formula (I) or groups convertible thereto.

20 10. A pharmaceutical composition comprising a compound of formula (I) as defined in any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

25 11. A method of treating or preventing diseases or disorders where an antagonist of a human orexin receptor is required, which comprises administering to a subject in need thereof an effective amount of a compound of formula (I) as defined in any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, without provisos a)-x).

30 12. A compound of formula (I) as defined in any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, without provisos a)-x), for use in the treatment or prophylaxis of diseases or disorders where an antagonist of a human orexin receptor is required.

13. The use of a compound of formula (I) as defined in any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, without provisos a)-x), in the manufacture of a medicament for the treatment or prophylaxis of diseases or disorders where an antagonist of a human orexin receptor is required.

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/EP 00/01150

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D413/12 A61K31/47 C07D215/46 C07D417/12 C07D401/12
A61P43/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 552 411 A (DENNIS M. DOWNING ET AL.) 3 September 1996 (1996-09-03) column 1 -column 2 ---	1,10
X	WO 98 58905 A (YAMANOUCHI PHARMACEUTICAL CO., LTD.) 30 December 1998 (1998-12-30) * page 26: compound 4 and 5 * ---	9 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

22 June 2000

Date of mailing of the international search report

14/07/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Van Bijlen, H

INTERNATIONAL SEARCH REPORT

International Application No PCT/EP 00/01150

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	RAMIYA R. AMARESH ET AL.: "A novel one-pot synthesis of 2-aminoquinolines from arylazidoketones by cyclization under Vilsmeier conditions" TETRAHEDRON:, vol. 54, no. 47, - 1998 pages 14327-14340, XP002140817 ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM., NL ISSN: 0040-4020 * page 14328, 14329, 14333 and 14334: compound 3a, 3b and 3c; page 14332, 14336 and 14337: compound 14 *	9
X	WO 98 08846 A (PFIZER INC.) 5 March 1998 (1998-03-05) * page 39, line 29-30; page 41, line 18 *	9
P,X	WO 99 09024 A (SMITHKLINE BEECHAM PLC) 25 February 1999 (1999-02-25) cited in the application claims 1,13	1,12
P,X	WO 99 38846 A (PROCEPT, INC.) 5 August 1999 (1999-08-05) page 27 -page 30	9
P,X	WO 99 17775 A (CEPHALON, INC.) 15 April 1999 (1999-04-15) * page 20-21: compound 1 and 2; page 20,26,27: compound 15 and 16 *	9

INTERNATIONAL SEARCH REPORT

International Application No. PCT/EP 00 01150

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 9 (partly)

The initial phase of the search revealed a very large number of documents relevant to the issue of novelty. So many documents were retrieved that it is impossible to determine which parts of the claim may be said to define subject-matter for which protection might legitimately be sought (Article 6 PCT). For these reasons, a meaningful search over the whole breadth of the claim is impossible.

The cited documents form a representative sample of the revealed documents of the last years.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/01150

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
US 5552411	A	03-09-1996		AU 5577096 A WO 9637474 A		11-12-1996 28-11-1996
WO 9858905	A	30-12-1998		AU 7933098 A		04-01-1999
WO 9808846	A	05-03-1998		AU 3355797 A BG 103192 A CN 1228091 A CZ 9900677 A EP 0925298 A HR 970452 A JP 2000502722 T NO 990892 A PL 331988 A ZA 9707652 A		19-03-1998 30-09-1999 08-09-1999 17-11-1999 30-06-1999 31-08-1998 07-03-2000 25-02-1999 16-08-1999 26-02-1999
WO 9909024	A	25-02-1999		AU 8741198 A EP 1003737 A		08-03-1999 31-05-2000
WO 9938846	A	05-08-1999		AU 2108099 A		16-08-1999
WO 9917775	A	15-04-1999		AU 9788298 A		27-04-1999